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Abstract  
 
Major histocompatibility complex (MHC) is at the center of immune 
responses that support survival, fitness and adaptation of mammalian 
species to the environment. These molecules are not only crucial for 
adaptive and innate immune responses against microorganisms and 
cancer cells but also play an important role in reproduction process and 
development of embryo during the preimplantation period. In the present 
study, we use murine embryonic stem cells (ESCs) as model to dissect the 
molecular mechanism involved in the regulation of MHC class I molecules 
during differentiation in vitro. MHC class I molecules are expressed at very 
low levels on murine ESCs and they are not induced by the 
immunomodulatory cytokine interferon gamma (IFNγ) despite the presence 
of IFNγ receptors on their cell surface. First, we showed that removal of 
leukemia inhibitory factor (LIF), a standard component of murine ES cell 
culture media required for the maintenance of a pluripotent state, did not 
result in up regulation of MHC class I expression in murine ESCs, 
presumably due to incomplete inactivation under these experimental 
conditions of STAT3 signaling pathway, which is used by LIF. However, 
the addition of LIF to differentiated cells in embryoid bodies strongly 
suppressed the expression of these molecules. Down regulation of STAT3 
in undifferentiated ESCs cultured in the presence of LIF significantly 
increased the expression of MHC class I molecules and this was further 
enhanced by IFNγ treatment. Flow cytometric analysis revealed that 
STAT1 is phosphorylated by IFNγ in STAT3 knockdown (KD) ESCs, 
whereas there was only weak or no phophorylation detected in mock 
siRNA 647-treated ESCs exposed to IFNγ. Luciferase reporter assay also 
indicated that GAS promoter responded to IFNγ much strongly in STAT3-
depleted ESCs than in intact cells, suggesting that ESCs do not respond 
to IFNγ at least partially due to inhibitory effects of STAT3-signaling 
components on STAT1-phosphorylation. Moreover, the down regulation of 
suppressor of cytokine signaling 3 (SOCS3) in STAT3 KD ESCs increases 
the possible regulation of STAT1 phosphorylation by SOCS3. No effect in 
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MHC class I molecules induction was observed in STAT3 KD ES-derived 
cardiomyocytes (ESCMs) indicating the differential regulation of these 
molecules during the course of differentiation from undifferentiated stage 
(ESCs) to differentiated stage (ESCMs). 
An additional mechanism by which STAT3 regulates MHC class I 
expression may involve epigenetic modification of MHC class I gene 
expression since Dnmt knockout (KO) murine ESCs showed upregulation 
of MHC class I molecules. Chromatin modifying gene Eed1 but not Dnmt1 
and Jmjd1 was significantly downregulated in STAT3 KD murine ESCs. 
Additionally, murine ESCs showed increased MHC class I expression and 
enhanced response to IFNγ after treatment with the DNA-
methyltransferase inhibitor 2,5-azacytidine and histone deacetylase 
inhibitor Trichostatin A.  
Modulation of MHC class I expression by STAT3 KD in ESCs reduced 
their lysis by activated syngeneic NK cells and increased their lysis by 
cytotoxic T cells compared to mock siRNA 647-treated ESCs. These data 
indicate that STAT3 pathway plays a dual role in modulating the MHC 
class I expression in ESCs. Interfering with the inhibitory pathways that 
suppress MHC class I expression in pluripotent ESCs may help to control 
teratoma formation from contaminating ESCs in therapeutic cell 
transplants and may also help to eradicate cancer cells and virus-infected 
cells that are known to frequently evade immune recognition by down 
regulating the MHC class I expression.  
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Zusammenfassung 
 
Der Haupthistokompatibilitätskomplex (MHC) ist der Mittelpunkt der 
Immunantwort, welche Überleben, Fitness und Anpassung der Säugetiere 
an die Umgebung gewährleistet. Die MHC Moleküle sind nicht nur für die 
adaptive und die angeborene Immunantwort verantwortlich, sondern 
spielen außerdem eine wichtige Rolle im Reproduktionsprozess und der 
Entwicklung des Embryos während der Präimplantationsphase. In der 
vorliegenden Arbeit nutzen wir murinen embryonale Stammzellen 
(mESCs), um die molekularen Mechanismen, die an der Regulation der 
MHC Klasse I Moleküle während der in vitro Differenzierung der 
Stammzellen beteiligt sind, zu untersuchen. MHC Klasse I Moleküle 
werden in murinen ESCs nur schwach exprimiert und werden trotz 
entsprechender Rezeptoren auf ihrer Zelloberfläche nicht vom 
immunmodulatorischen Zytokin Interferon Gamma (IFNγ) induziert. 
Zunächst zeigten wir, das in Abwesenheit vom Leukemia inhibierenden 
Faktor (LIF), welcher als Standardmediumkomponente muriner ESC Kultur 
zur Erhaltung der Pluripotenz eingesetzt wird, nicht zur Hochregulierung 
der MHC Klasse I Molekülexpression führte. Dieser Umstand könnte auf 
eine unvollständige Inaktivierung des STAT3 Signalweges, über welchen 
LIF reguliert,  unter den verwendeten experimentellen Konditionen zu 
erklären sein. Allerdings führte die Zugabe von LIF zu differenzierenden 
embryonalen Körpern (EB) zu einer starken Unterdrückung der MHC-
Moleküle. Abregulierung von STAT3 in undifferenzierten ESCs, welche in 
Anwesenheit von LIF kultiviert wurden, erhöhten ihre MHC Klasse I 
Molekülexpression signifikant. IFNγ-Behandlung verstärkte diese 
Expression. Mittels Durchflusszytometrie konnte gezeigt werden, dass 
STAT1 in ESCs von IFNγ phosphoryliert wird, wenn STAT3 in der Zelle 
ausgeschaltet wird. Im Gegensatz dazu war nur eine schwache bis keine 
Phosphorylierung in ESCs unter IFNγ-Einfluss detektierbar, welche mit 
Kontroll-siRNA-647 behandelt wurden. Der Luziferasetest ergab ebenfalls, 
dass der GAS promotor in Zellen ohne STAT3-Expression weitaus stärker 
auf IFNγ reagierte, als in Zellen mit STAT3-Expression. Diese Daten 
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lassen darauf schließen, dass ein Grund, warum ESCs nicht auf IFNγ 
reagieren, auf inhibierende Effekte von Komponenten aus dem STAT3-
Signalweg auf die STAT1-Phosphorylierung zurückzuführen sind. 
Darüberhinaus  führte die Abregulierung des Unterdrückerzytokinsignal 3 
(SOC3) in STAT3-defizienten ESCs zu einem Anstieg der möglichen 
Regulation der STAT1-Phosphorylierung durch SOCS3. In STAT3-
defizienten Kardiomyozyten, welche aus ESCs generiert wurden (ESCMs), 
war keine Induktion der MHC Klasse I Moleküle zu beobachten. Dies weist 
auf eine verschiedene Regulierung dieser Moleküle vom undifferenzierten 
zum differenzierten Zustand hin. Der Mechanismus durch den STAT3 
direkt auf die MHC Klasse I Expression wirkt mag auch epigenetische 
Modifikationen mit einschließen, da murine DNMT Knockout (KO) ESCs 
ebenfalls eine Hochregulierte MHC Klasse I Expression zeigten. In STAT3 
KD murinen ESCs wurde das Gen Eed1 signifikant herabreguliert, 
während die Expreession von Dnmt1 und Jmjd1 nicht signifikant verändert 
wurde. Außerdem zeigten murine ESCs erhöhte MHC Klasse I Expression 
und eine verstärkte Antwort auf IFNγ nach Behandlung mit dem DNA-
methyltransferase Inhibitor 2,5-azacytidine und dem Histondeacetylase 
Inhibitor Trichostatin A. Im Vergleich zu mock siRNA 647-treated ESCs 
wurden STAT3 KD ESCs auch weniger effizient von aktivierten sygenen 
NK Zellen und effizienter von zytotoxischen T-Zellen lysiert. Diese Daten 
weisen darauf hin, dass STAT3 eine duale Rolle bei der Modulation der 
MHC Klasse I Expression in ESCs spielt. 
Die Auseinandersetzung mit den inhibierenden Signalwegen, welche die 
MHC Klasse I Molekülexpression in ESCs unterdrücken, kann hilfreich 
sein bei der Kontrolle von Tumorbildung durch kontaminierende ESCs in 
therapeutischen Zelltransplantationen, sowie bei der Vernichtung von 
Krebs- und virusinfizierten Zellen, die bekannt dafür sind der 
Immunerkennung durch Abregulierung der MHC Klasse I Moleküle zu 
entkommen. 
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I.  Introduction 
I.1.  Organization of the immune system 
The major role of the immune system is to protect against disease by 
recognizing and killing pathogens such as bacteria, viruses, fungi and 
parasites as well as by eliminating abnormal, transformed somatic cells. If 
immune system is defective, the organism will die due to infection by 
microorganisms or development of cancer. For protection of our body, 
various immune mechanisms evolved that recognize and kill infectious 
agents. The primitive forms of the immune system in bacteria, 
invertebrates, plants and insects are based on antimicrobial enzymes, 
toxins and peptides called – defensins. Humans have typical vertebrate 
immune system that is composed of many types of proteins, cells, tissue 
and organs that work and interact in a more complex and sophisticated 
way to defend against various types of pathogens (Beck et al. 1996). The 
human immune system is divided into two main parts: humoral and 
cellular. Humoral immunity deals with the infectious agents in blood and 
body tissues and is mediated by the action of different soluble factors such 
as lysosome, complement system, cytokines, acute phase proteins and 
antibodies. The cellular part of the immune system is responsible for 
phygocytosis, processing of pathogens, secretion of soluble mediators of 
immune reactions and elimination of body cells that have been infected 
with intracellular pathogens. Both humoral and cellular branches of the 
immune system have their unspecific (innate, native) and specific 
(adaptive, acquired) components (Table1).  
Table 1. The characteristics of innate and adaptive immune responses 
Characteristic Innate (native)  Adaptive (acquired) 
Species distribution Nearly all forms of life Only in jawed vertebrates 
Pathoden specificity Low Very high 
Diversity Limited High (∼ 109) 
Memory None Yes 
Secondary response None Yes 
Clonality None Yes 
Kinetic of response Immediate  Delayed 
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Innate immunity 
The innate immune system refers to the first line of defense against 
infection that a species possesses as basic resistance to disease. The 
responses in this system are non-specific and have no memory or long 
lasting protective immunity. These responses are phylogenetically old 
(found in plants, fungi, insects and primitive multicellular organisms) and 
have a limited repertoire of recognition molecules (Litman et al. 2005). 
They encounter possible pathogens and destroy in daily life and the 
disfunctions of specific components in this system lead to rare diseases 
such as leukocyte adhesion deficiencies, congenital neutropenia, chronic 
granulomatous disease, various complement deficiencies and others.  
The cells of the innate immune system include natural killer cells, 
basophils, eosinophils including phagocytic cells such as neutrophils, 
dendritic cells and macrophages. The main function of these cells is to 
recognize and eliminate the pathogens from the body. (Guermonprez et al. 
2002; Middleton et al. 2002; Kariyawasam et al. 2006; Krishnaswamy et al. 
2006). In addition, professional antigen-presenting cells (macrophages, 
dendritic cells and B cells) brake down pathogens in a process of antigen 
processing and presentation, which is required for activation of cells of the 
adaptive immune system. 
 
Adaptive immunity 
Adaptive immunity is acquired in jawed vertebrates including human and is 
activated by the innate immune system. When an immune system 
encounters foreign molecules (antigens), the cells and other components 
of adaptive immunity attack and process each antigen. Intracellular 
antigens (e.g. foreign viral proteins) are presented by MHC class I 
molecules to CD8+ T cells. Extracellular antigens are processed in the 
endolysosomal system and presented by MHC class II molecules to CD4+ 
T cells (more details about antigen presentation are found in next chapter). 
This type of immunity takes time to develop after exposure to a new 
antigen. But once memory is formed, the immune response is mounted in 
a more effective and rapid way against previously encountered antigens 
(Pancer et al. 2006).  
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The fundamental characteristics of the acquired immune system are its 
specificity, diversity, ability to learn and, by retaining the memory of a 
previous encounter with a pathogen, prepare the body against the future 
challenges by the same pathogen. Four distinct but related cell-membrane 
molecules are responsible for a highly specific antigen recoginition. These 
are membrane-bound antibodies on B cells, T-cell receptors, class I MHC 
molecules and class II MHC molecules. These molecules play a unique 
role in antigen recoginition, ensuring that the immune system can 
recognize and respond to the various types of antigen that it encounters 
(see detailed information in the text below). 
The main cells of acquired immunity are lymphocytes which are a type of 
white blood cells. They enable body’s immune system to discriminate self 
from non-self and to remember antigens. Lymphocytes migrate without 
any restriction in the blood stream and lymphatic system and infiltrate into 
tissues as needed. Lymphocytes are divided into two classes: B cells and 
T cells. 
B cells develop in the adult bone marrow or the fetal liver. The antigenic 
specificity of each B cell is determined by the membrane-bound antigen-
receptor (antibody) expressed by the cell. The B cell antigen receptor 
(BCR) is composed of membrane immunoglobulin (mIg) molecules 
(antibody) and associated Igα/Igβ (CD79a/CD79b) heterodimers (α/β). The 
mIg subunits bind antigen, resulting in receptor aggregation, while the α/β 
subunits transduce signals to the interior of the cell. The complexity of 
BCR signaling permits many distinct outcomes, including survival, 
tolerance or apoptosis, proliferation, and differentiation into antibody-
producing cells or memory B cells. The outcome of the response is 
determined by the maturation state of the cell, the nature of the antigen, 
the magnitude and duration of BCR signaling, and signals from other 
receptors such as CD40 and BAFF-R. The antibody on a B cell can 
recognize epitopes on macromolecules with incredible precision. The 
random gene rearrangements during B-cell maturation in the bone marrow 
generate an enormous number of different antigenic specificities. Other 
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functions for B cells include antigen presentation, cytokine production and 
lymphoid tissue organizations.  
           T cells develop in the thymus where they learn how to differentiate self 
from non-self (Zinkernagel 1978). T cells which ignore self antigen 
molecules are allowed to mature and leave the originating place. T cells 
are abundantly present in lymphatic system and migrate to secondary 
lymphoid organs such as spleen, lymph nodes, tonsils, appendix and 
Payer’s patches in the small intestine. There are several classes of T cells 
that can be distinguished by expression of specific molecules on their cell 
surface: CD8+-expressing cytotoxic T cells, CD4+-expressing helper T 
cells, and CD4+CD25+-expressing regulatory T cells. CD8+ T cells are 
involved directly in the killing of infected cells, while helper T (Th) cells 
augment the responses of other lymphocytes by secreting various 
cytokines (Abbas et al. 1996; Harty et al. 2000; Radoja et al. 2006). CD4 
helper T cells produce two types of cytokines - Th1-type and Th2-type. 
Th1-type cytokines mainly include IFNγ which tend to produce the 
proinflammatory responses responsible for killing intracellular pathogens 
and for perpetuating auoimmune responses. The Th2-type cytokines 
include interleukins 4, 5 and 13, which are associated with promotion of 
IgE and eosinophilic responses in atopy, and also interleukin-10, which 
has an anti-inflammatory properties. In excess, Th2 responses will 
counteract the Th1 mediated microbicidal action. Regulatory T cells 
produce molecules that help to end the immune responses (Sakaguchi 
2005). An additional type of T cells are gamma/delta (γδ) T cells which 
share the characteristics of helper T cells, cytotoxic T cells and NK cells. 
They are considered to be linker of adaptive and innate immunity 
(Holtmeier et al. 2005). T cells are especially important in cell-mediated 
immunity, which is the defense against tumor cells and pathogenic 
organisms inside body cells and are also involved in graft rejection 
reaction. 
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I.2. Major Histocompability Complex (MHC) and their role in 
immunorecognition 
All vertebrate cells except erythrocytes express histocompatibility 
molecules on their surfaces. They are mostly responsible for immune 
responses to protein antigens are encoded by a region of highly 
polymorphic genes, called ther major histocomaptibility complex. Human 
MHC molecules are known as human leckocyte antigens (HLA) and 
mouse as histocompatibility 2 (H-2) antigens (Gill et al. 1978).  
Their genetic loci H-2k, H-2d and H-2L are present on chromosome 17 in 
mice while HLA-A, HLA-B and HLA-C are present on chromosome 6 in 
humans. Each MHC class I gene encodes a single transmembrane 
polypeptide chain known as alpha (α), which is folded into three 
extracellular globular domains (α1, α2, α3), of which the domains α1 and 
α2 are highly polymorphic. Each α-chain is non-covalently associated with 
a protein called β2-microglobulin. MHC class I molecules present peptide 
fragments of endogenous protein antigens to CD8+ T cells. These MHC 
class I/peptide complex is recognized by T cell receptor (TCR). The 
random rearrangement of the TCR genes is capable of generating about 
109 unique antigenic specificities. The TCR is composed of two different 
heterodimeric protein chains. The α/β receptor chains are present in 95% 
of T cells (CD4 and CD8 T cells) while γ/δ receptor chains consist of only 
5% of T cells (γδ T cells). CD3 molecules (CD3-γ, δ, ε, and ζ), which are 
assembled together with the TCR heterodimer, possess a characteristic 
sequence motif for tyrosine phosphorylation, known as ITAMs 
(Immunoreceptor Tyrosine-based Activation Motifs). The TCR 
polypeptides themselves have very short cytoplasmic tails, and all 
proximal signaling events are mediated through the CD3 molecules. The 
interaction of an antigenic peptide with the TCR-CD3 complex generates 
the initial signal 1. TCR activation is regulated by various costimulatory 
receptors/molecules such as CD28, B7-1, B7-2 and CD45. CD28 provides 
an essential co-stimulatory signal (signal 2) during T cell activation, which 
augments the production of interleukin-2 (IL-2) cytokine, increases T cell 
proliferation and prevents the induction of anergy and cell death. On the 
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other hand, engagement of CTLA-4, a close relative of CD28, by B7 
inhibits T-cell activation. Engagement of the TCR with MHC class I/peptide 
complex initiates positive (signal-enhancing) and negative (signal-
attenuating) cascades that ultimately result in cellular proliferation, 
differentiation, cytokine production, and/or activation-induced cell death. 
MHC molecules play a role in intercellular recognition and in discrimination 
between self and nonself. They determine whether transplanted tissue is 
accepted as self (histocompatible) or rejected as foreign 
(histoincompatible). The MHC plays a critical role in antigen recognition by 
T cells. The phenomenon that a given T cell recognizes a peptide antigen 
only when it is bound to a host own MHC molecules, is known as the MHC 
restriction phenomenon. MHC restriction is due to positive selection of 
thymocytes bearing receptors capable of binding self-MHC molecules. On 
the other side, negative selection by elimination of thymocytes bearing 
high-affinity receptors for self-MHC molecules alone or self-antigen 
presented by self-MHC results in self-tolerance. Both MHC restriction and 
self-tolerance are necessary to generate mature T cells that are self-MHC 
restricted and self-tolerant.  
Allorecognition refers to the T-cell recognition of genetically encoded 
polymorphisms within the members of the same species. T-cell recognition 
involves both the MHC molecules and its associated peptide ligand. The 
polymorphic residues located within the peptide binding groove of the 
MHC and inaccessible to the T cell receptor can greatly affect selection 
and recognition of bound peptides. The antigenic impact of MHC 
polymorphisms is profoundly amplified by these peptide differences 
between histoincompatible individuals and result in the high frequency of 
alloreactive cells. Moreover, the frequency of T cells responding to any 
conventional foreign antigen presented on self-MHC molecules usually 
amonts to 0.01-0.001% of all T cells. However, T cell-mediated 
allorecognition is a rapid and vigorous process because up to 1% of 
peripheral T cells in each individual can cross-react with allogeneic MHC 
antigens (Lindahl et al. 1977; Suchin et al. 2001). 
MHC molecules are highly polymorphic. Each individual has multiple 
genetic loci encoding MHC molecules, so it is very rare for two individuals 
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to have same set of MHC proteins leading to the problem of tissue 
matching. But on the other hand, MHC molecule polymorphism is very 
important from the point of view of disease resistance because allelic 
forms of MHC genes may encode molecules that serve as receptors for 
pathogens including viruses and bacterial toxins. The MHC genes are 
divided into three classes: the MHC class I and class II genes, which 
encode the antigen-presenting MHC molecules, and the class III genes, 
which encode the genes with both known or unknown immune functions 
(1999; Shiina et al. 2004; Trowsdale et al. 2004; Deakin et al. 2006).  
Antigens bound by MHC class I molecules are generated by proteolytic 
degradation of pathogen-encoded (e.g. by viruses) or normal host proteins 
in the cytosol or nucleus of cells. The major protease involved in this 
process is the proteasome, which cleaves all intercellular proteins into 
short peptides (Figure 1). Peptides generated in the cytosol are further 
cleaved by aminopeptidases to a length of 8-9 amino acid residues optimal 
for binding to MHC class I molecules. Longer proteasome products as well 
as correctly trimmed antigenic peptides are transported into rough 
endoplasmic reticulum (ER) by heterodimeric transmembrane protein 
channel called transporter associated with antigen processing (TAP). In 
the ER, longer peptides can be further edited by ER-aminopeptidases 
ERAP1 and ERAP2 (Saric et al. 2002). Peptides of 8-9 residues in length 
are then captured by empty MHC heterodimers in the lumen of the ER with 
the help of several ER resident proteins such as calnexin, tapasin and 
protein disulfide isomerase. Finally, the stabilized MHC class I-antigenic 
peptide complex is carried out to the cell membrane via Golgi complex and 
is recognized on the cell surface by CD8+ T cells (Li et al.; Rock et al. 
1999; Hansen et al. 2009). 
MHC class II molecules are mainly present on professional antigen-
presenting cells (APCs) such as dendritic cells, macrophages and B 
lymphocytes. They are also expressed on thymic epithelial cells. In mice, 
their genetic loci are called I-A and I-E and in humans HLA-DP, HLA-DQ 
and HLA-DR. Each MHC class II gene encodes heterodimeric chains (α 
and β) with two conserved immunoglobulin-like domains (α2 and β2) close 
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to the membrane and two antigen-binding polymorphic amino-terminal 
domains (α1 and β1) farthest from the membrane. MHC class II molecules 
bind and present peptide fragments of exogenous, extracellular protein 
antigens to CD4+ helper T cells. Exogenous antigens that are engulfed by 
APCs by means of phagocytosis or endocytosis are processed in the 
endosomal-lysosomal antigen processing pathway (Sant et al. 1994; 
Lennon-Dumenil et al. 2002; Gelin et al. 2009) (Figure 1).  
 
                          
           Figure 1. The antigen presentation pathways in dendritic cells. “All dendritic cells 
(DCs) have functional MHC class I and MHC class II presentation pathways. MHC class I 
molecules present peptides that are derived from proteins degraded mainly in the cytosol, 
which in most DC types comprise almost exclusively endogenous proteins (synthesized 
by the cell itself). MHC class II molecules acquire peptide cargo that is generated by 
proteolytic degradation in endosomal compartments. CD8+ DCs have a unique ability to 
deliver exogenous antigens to the MHC class I (cross-presentation) pathway, although 
the mechanisms involved in this pathway are still poorly understood. The bifurcated arrow 
indicates that the MHC class II and the MHC class I cross-presentation pathways may 
compete for exogenous antigens in CD8+ DCs, or that the endocytic mechanism involved 
in internalization of a given antigen may determine whether it is preferentially delivered to 
MHC class II pathway or the MHC class I cross-presentation pathway. TAP, transporter 
associated with antigen processing”. (Villadangos and Schnorrer, Nature Reviews 
Immunology, 2007) 
 
 
           I.3. Interferon gamma (IFNγ) and regulation of MHC molecules 
Interferons (IFNs) are proteins made and released by host cells in 
response to the presence of pathogens or tumor cells. They are typically 
divided into type I (alpha and beta) and type II (gamma) classes. IFNs are 
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multifunctional secreted proteins having similar functions activating partly 
overlapping pattern of induced genes related to cell growth regulation and 
anti-viral and immune defense (Stark et al. 1998). Interferon-gamma 
(IFNγ), a 34 KDa protein, was discovered in 1965 as an antiviral protein 
(Boehm et al. 1997). IFN activity may be divided into acid stable and acid 
labile activity. All cells produce the acid stable activity while acid labile is 
only produced by lymphocytes, and this is known as IFNγ. Besides 
antiviral function, IFNs have broader range of anti-proliferation and pro-
inflammatory activities. IFNγ exposure to cells can up-regulate MHC class I 
expression on their cell surface and enhance cytotoxic T-lymphocytes 
(CTLs) recognition (Rosa et al. 1988). In this way, CTLs destroy bacteria 
and virus infected cells via CTL epitope/MHC class I complexes on the 
surface of target cells (Boehm et al. 1997). The components of MHC class 
I antigen processing machinery are up-regulated by IFNγ through 
JAK/STAT signal transduction pathway (Kohlhuber et al. 1997; Wu et al. 
1997; Fruh et al. 1999). IFNγ performs its biological functions through 
binding to IFNγ-receptor (IFNGR). IFNGR is composed of two subunits (α 
and β) and is present on all nucleated cells. IFNGR-α chain associates 
with Janus active kinase-1 (JAK1) and signal transducer and activator of 
transcription 1 (STAT1) while IFNGR-β chain binds to JAK2 (Figure 2). 
IFNγ bound to its receptor leads to the trans-phosphorylation and 
reciprocal activation of JAKs which subsequently activate STAT1 by 
phosphorylation at tyrosine 701 (Y701) and serine 727 (S727) DNA-
binding site. After activation the phosphorylated STAT1 dimerizes in the 
cytosol and is translocated into the nucleus to activate IFNγ-inducible 
genes by binding to the gamma interferon activation site (GAS) elements 
in their promoter regions. The nuclear transport of STAT1 dimers occurs 
through nuclear pore complexes and is dependent on heterodimeric 
importin receptors, which, on one side, bind to the nuclear localization 
signal of the cargo (importin α subunit) and, on the other side, enable 
docking of the protein cargo on the cytoplasmic site of the nuclear pore 
complex (importin β subunit). There are six different α-importin (α1-α6) 
and one β-importin (β1). Various α-importins are differentially expressed in 
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different tissues and are responsible for nuclear import of different cargo 
proteins. Nuclear import of activated STAT1 occurs through importin-α1 
(McBride et al. 2002). In the nucleus, phosphorylated STAT1 dimers 
activate IFNγ inducible target genes including MHC class I heavy chain 
and light chain molecules and several components of the MHC class I 
antigen processing and presentation pathway (Fruh et al. 1999). IFNγ also 
activates some important transcription factors from interferon regulatory 
factor (IRF) family (especially IRF-1 and IRF-8). They have a capacity to 
bind to IFNγ regulated response elements in promoter region of genes and 
stimulate the transcription of IFNγ stimulated genes (ISGs) such as LMP2, 
LMP7, TAP1, TAP2 and tapasin (Taniguchi et al. 2002). IRF-1 expression 
is induced by IFNγ through STAT1-dependent fashion over a period of 
hours (Harada et al. 1994; Pine et al. 1994) and it is not directly activated 
by IFNγ. IRF-1 cooperates with STAT1 to transcribe ISGs which require 
intact IRF-1 and STAT1 binding sites to be optimally transcribed. IRF-1 
plays an important role in regulating MHC class I gene expression (Mori et 
al. 1999). However, other IFNγ -induced factors such as p48, also up-
regulate MHC class I gene expression in STAT1 independent manner. 
This describes the diversity of regulation of MHC class I expression 
mediated by IFNγ (Bluyssen et al. 1996; Kimura et al. 1996; Majumder et 
al. 1998).  
MHC class II trans-activator (CIITA) is a transcriptional factor that 
regulates the expression of MHC class II (Chang et al. 1996). CIITA is also 
efficiently induced by IFN-γ through a complex consisting of upstream 
factor 1 (USF-1) and STAT1 (Muhlethaler-Mottet et al. 1997; Muhlethaler-
Mottet et al. 1998). This is an additional example of co-operation of STAT1 
with other transcriptional factors. In contrast, the transcription factors 
STAT3, STAT5, NF-κB and AP-1 are induced by IFN-γ without the 
cooperation of STAT1. In some cases, STAT3 and STAT5 are activated by 
IFNγ to compensate the absence of STAT1 (Meinke et al. 1996; Ramana 
et al. 2000; Ramana et al. 2005) but during anti-viral response, STAT3 can 
not compensate the loss of STAT1 (Horvath et al. 1996). Because, 
biologically active STAT1 must be full length and phosphorylated on both 
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tyrosine and serine residues for full IFNγ antiviral activity. Furthermore, 
these closely related STAT proteins (STAT1 and STAT3) are not 
functionally redundant in their ability to establish the antiviral effect.  
Previous reports demonstrated that the expression and phophorylation of 
STAT3 was increased in cells deficient of STAT1 (Ramana et al. 2005). 
But, this was not true in all STAT1-deficient strains (Gough et al. 2007). 
The reason for this discrepancy is still unclear and might be dependent on 
animal strain.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The IFNγ signaling pathway in all nucleated cells. IFNγ binds to its receptor 
IFNGR1/R2 and leads to activation of JAK1/2 which phosphorylates STAT1 on Tyr701 or 
Ser727 residues. Active STAT1 dimerizes and goes into the nucleus by nuclear import 
proteins importin α1/β. Active STAT1 binds to the IFNγ-activated site (GAS) in promoter 
region leading to the induction of IFNγ-inducible genes including TAP1,TAP2, LMP2, 
LMP7, MHC I heavy chain and β2M. SHP1, IRF1 and IRF2 act as positive regulators 
while SOCS1, PIAS1, PTP1B and SHP2 act as negative regulators of this pathway. 
LIF/IL-6 inhibits through STAT3 pathway the IFNγ induced STAT1 signaling. (Leonidas C. 
Platanias, Nature Reviews Immunology, 2005) 
 
The significance of the NF-κB pathway in IFNγ signaling is not known so 
far. However, IFNγ can induce DNA binding of NF-κB in the absence of 
STAT1 in some primary fibroblasts. This cell restricted phenomenon 
reveals that this may not be the main mechanism of STAT1 independent 
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transcriptional effects of IFNγ (Deb et al. 2001). The activator protein 1 
(AP-1) is the family of dimeric transcription factors, which are rapidly 
activated by IFNγ and required for transcription of several IFNγ stimulated 
genes (Clarke et al. 2003; Gough et al. 2007). AP-1 DNA binding activity is 
increased rapidly by IFNγ independently of JAK1/2 or STAT1. AP-1 activity 
is also required for transcription of several ISGs with or without co-
operating with STAT1 (Gough et al. 2007). 
 
 
I.4. Role of STAT1:STAT3 signaling in biological systems 
Interferons and gp130 family of cytokines play a major role in regulating 
immune responses and in mediating cellular decisions during growth and 
development. Signal transducer and activators of transcription, especially 
STAT1 and STAT3, are the main targets of type I and type II interferons 
and cytokines belonging to the gp130 family such as interleukin 6 (IL-6) 
and leukemia inhibitory factor (LIF). STAT3 promotes cell 
proliferation/survival and immune tolerance and inhibits inflammation, 
while STAT1 counteracts proliferation and supports innate and adaptive 
immune responses. IFNγ mainly activates prolonged STAT1 activation 
through JAK1 and JAK2 while type I IFNs activate the distinct 
transcriptional complex including STAT1, STAT2 and ISGF3. The 
cytokines of IL-6 family activate JAK1, JAK2 and TYK2 through specific 
leukemia inhibitory factor receptor (LIFR) leading to the prolonged 
phosphorylation of STAT3. LIF acts through a high-affinity receptor 
complex composed of a low affinity LIF binding chain (LIFR, also known as 
CD118) and high-affinity converter subunit gp130. 
STAT1 pathway activates the expression of apoptotic genes like 
caspases, death receptors and ligands, and nitric oxide synthase (Allione 
et al. 1999; Fulda et al. 2002). On the other side, it negatively regulates 
the expression of prosurvival genes such as Bcl-xL, and Bcl-2 (Stephanou 
et al. 2000). STAT3 target genes differ according to cell type and 
environmental circumstances. In general, STAT3 induces anti-apoptotic 
genes of Bcl family to prevent apoptosis and it promotes proliferation 
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through the induction of oncogenes and cell cycle regulatory genes such 
as cyclin D1, c-myc and pim-1 (Chin et al. 1996; Dimberg et al. 2003; Xiao 
et al. 2006). STAT1 and STAT3 exert opposing roles in inflammation. IFN-
mediated STAT1 activation acts as a proinflammatory factor by inducing 
tissue apoptosis and a number of genes that favor activation and 
recruitment of immune cells to the side of inflammation. STAT1 activation 
by type I and II IFNs advocates antigen presentation by enhancing the 
expression of MHC class I and MHC class II molecules and the 
components of antigen-processing machinery (Lee et al. 1996; Brucet et 
al. 2004; Marques et al. 2004; Rouyez et al. 2005). In contrast, STAT3 
mediates the functions of major anti-inflammatory cytokine IL-10 which 
maintains the balance between activation and deactivation of mononuclear 
cells and downregulates the surface expression of MHC molecules 
(Donnelly et al. 1999). STAT3 activated IL-10 also directly inhibits IFN-
induced gene transcription partly by downregulating STAT1 activation due 
to inhibition of its tyrosine phosphorylation (Ito et al. 1999). Interestingly, 
STAT1 is usually considered as a tumor suppressor while STAT3 is known 
as an oncogene since it is constitutively expressed in almost 70% of solid 
and hematological tumors (Turkson et al. 2000; Turkson 2004; Kim et al. 
2007). STAT1 directly controls tumor cell expansion by up regulating many 
pro-apoptotic and anti-proliferative genes in cancer cells. In contrast, 
STAT3 constitutive activity is necessary for survival and proliferation of 
many different kinds of established or primary cancer cells (Turkson et al. 
2004; Kim et al. 2007) and STAT3 allows cancer cells to escape from cell-
mediated immune system by enhancing the secretion of dendritic cell 
inhibitors such as IL-10 and VEGF (Wang et al. 2004). Therefore, the 
balance between STAT3 and STAT1 activity is important for homeostasis 
and physiology of normal cells (Figure 3).  
Although STAT1 and STAT3 play opposing roles in cell survival, 
proliferation, apoptotic death or inflammation, the counterbalance between 
STAT1 and STAT3 may decide the result of cytokine treatment and 
pathological responses. In fact, previous reports demonstrated that STAT1 
or STAT3-deficient cells have reciprocal STAT1:STAT3 regulatory 
mechanisms and relative affluence of STAT3 or STAT1 may play a role in 
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shaping the biological effects of their main activating cytokines (Costa-
Pereira et al. 2002; Qing et al. 2004; Gimeno et al. 2005; Tanabe et al. 
2005). For example, in absence of STAT3, gp130 cytokines strongly 
modify STAT1 activation profiles and trigger prolonged phosphorylation of 
STAT1 upregulating multiple IFNγ inducible genes in a number of cell 
types (Costa-Pereira et al. 2002).  
 
 
Figure 3.  The importance of balanced expression/activation of STAT1 and STAT3 
in tumor setting. When STAT3 activation and/or expression overwhelm, tumor 
development and maintenance are favored. The presence of soluble factors such as IL-
10 induces tolerance in immune cells; tumor cell proliferation and survival are favored not 
only directly, but also indirectly, by the enhancement of angiogenesis. On contrary, the 
prevelance of STAT1 activation directly blocks cell cycle progression and induces 
apoptosis of cancer cells. Moreover, STAT1 favors the generation of an adequate 
immune response against the tumor. (Regis et al, Seminars in Cell and Developmental 
Biology, 2008) 
 
 
These findings indicate that STAT3 downregulates STAT1 activity (IFNγ 
responses) and allow LIF/IL-6 specific responses in normal cells. Each 
specific cell type has characteristic STAT protein levels. The proteins of 
the suppressor of cytokine signaling (SOCS) family are induced as 
immediate early genes downstream of different STATs and inhibit STATs 
phosphorylation as a negative feedback mechanism (Chen et al. 2000). 
Fascinatingly, both SOCS1 and SOCS3 work not only as feedback 
mechanisms to quantitatively regulate STAT1 and STAT3 activation 
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respectively, but they can also finely adjust STAT1 or STAT3 mediated 
responses. For example, STAT3-dependent SOCS3 induction can prevent 
STAT1 activation and vice versa by inhibiting the JAKs in Con-A induced 
heapatitis in hepatocytes (Hong et al. 2002; Wormald et al. 2006). 
 
 
I.5. Allorecognition of embryo and expression of MHC molecules in 
the course of embryonic development 
Allorecognition attributes to T-cell recognition of genetic polymorphisms 
between members of same species. MHC molecules are the main targets 
of the immune responses to allogeneic tissues which are present on the 
donor cells. There are two pathways of allorecognition: direct and indirect 
(Lechler et al. 1982). Direct recognition involves the recognition by 
recipient T cells of intact donor MHC molecules complexed with peptide on 
donor antigen presenting cells. On contrary, the requirement of indirect 
recognition is that recipient antigen presenting cells (APCs) process the 
donor-MHC antigen prior to presentation to recipient T cells in a self-
restricted manner. Therefore, the direct and indirect alloresponses are 
governed by different APCs and differ in their cellular mechanisms (Figure 
4).  
Allorecognition is a basic system that animals use to preserve individuality. 
Although embryos are usually semiallogeneic with their mother, viviparous 
animals including human beings are required to allow these embryos to 
develop inside the mother’s body eliminating an ‘invasion’ by nonself. The 
embryo is directly exposed to the maternal immune system during 
pregnancy and embryonic cells can be found in maternal organs and blood 
in mice and humans (Liegeois et al. 1981; Guetta et al. 2003). This 
provides ample opportunities for the maternal immune system to recognize 
fetal alloantigens. However, embryo is not destroyed indicating that the 
immune system is tolerant of the fetal presence. It has been shown that 
maternal tolerance of the embryo in allogeneic pregnancy is dependent 
upon CD25+ regulatory T (Treg) cells but CD25+ Treg cells play no role 
during late stages of pregnancy (Shima et al. 2010; Aluvihare et al. 2004), 
indicating the involvement of other mechanisms. Interestingly, maternal 
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and fetal cells are involved in the establishment of the tolerogenic 
environment having overlapping molecular mechanisms. The maternal 
endometrium expresses the immunosuppressive factors TGF-β, Galectin-1 
(GAL-1) and thymic stromal lymphopoietin (TSLP) (Simpson et al. 2002; 
von Wolff et al. 2005). They induce Treg cells and Th2 responses and 
inhibit Th1 response providing tolerogenic environment. Both the maternal 
decidua and fetal trophoblast express indoleamine 2,3-dioxygenase (IDO) 
(Kamimura et al. 1991) which induces Treg cells and inhibits the activation 
of T cells and NK cells (Frumento et al. 2002). Crry is also expressed by 
fetal and maternal cells and it stops deposition of the complement proteins 
C3 and C4 to stop the formation of the cytosolic membrane attack complex 
(Weigle et al. 1983; Molina et al. 1992; Kim et al. 1995). Human villous 
cytotrophoblast cells also express non-classical HLA class Ib HLA-G 
molecules which help to evade cytotoxic NK activity and induce the 
tolerogenic phenotype of dendritic cells. Fas-L expression on these cells 
also helps to kill activated T cells via apoptosis (Le Bouteiller et al. 1999; 
Fournel et al. 2000; Hviid 2006; Carosella et al. 2008). 
In mammals the expression of MHC genes is developmentally 
programmed. After fertilization, a hierarchical order of gene expression 
takes place including the MHC genes. In order to understand how the 
developing embryo avoids rejection, it is essential to know if, and when, 
MHC class I expression occurs during embryonic development. It is well 
postulated that a possible route of escape of the embryo from maternal 
rejection is by down-modulating the MHC. This down-modulation of MHC 
genes occurs either at the feto-maternal interface and/or on the surface of 
other embryo cells. HLA class I and II are absent while HLA-G and β2M 
are present in human blastocyts and preimplantation embryos (Roberts et 
al. 1992; Jurisicova et al. 1996). Human trophoblasts are resistant to NK 
cell attack, possibly as a consequence of the presence of HLA-G, which 
ensures that NK cells detect the trophoblast as normal self. It is possible, 
that expression of certain MHC products is advantageous for the survival 
of the early embryo. The selective expression of MHC products during 
development is potentially subject to modulation, by a fluctuating pattern of 
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Th1-type and Th2-type cytokines, maternal hormones and other cellular 
interactions. Unexplained human reproductive failure is quite common and 
has often associated with MHC products (Christiansen et al. 1997). If MHC 
determinants were to be expressed in vivo, then cytotoxic T-cell attack 
could occur, resulting in spontaneous abortion.  
The onset of expression of MHC class Ia, class Ib, β2M, TAP1 and TAP2 
in murine embryonic development is shown in Table 2 (Sprinks et al. 1993; 
Cooper et al. 1998).  
 
Table 2. Detection of MHC and transporter associated with antigen 
processing (TAP) mRNA and protein products during preimplantation 
mouse embryonic development 
 
 1-cell stage 2-cell stage 8-cell stage Blastocyst 
 Protein mRNA Protein mRNA Protein mRNA Protein mRNA
MHC class Ia 
(H-2Db) 
+ - + + + + + + 
MHC class Ib 
(Q7/9) 
+ + + + + + + + 
β2M - - + - + + + + 
TAP1 - + - + - + + + 
TAP2 - - - - - - - - 
 
Note: symbols in parentheses indicate presence (+) or absence (-) of mRNA transcripts, 
as detected by reverse transcription-polymerase chain reaction, and protein products, as 
detected by indirect immunofluoresence. Based on data from: Sprinks et al, (1993), 
sprinks (1994), Cooper et al. (1998) and Cooper (1998). 
 
 
Taken together these data suggest that, at least for mice, MHC class I 
complexes composed of heavy chain and β2M are present at the surface 
of embryos at very early stages of development. However, they are 
unlikely to be functional in the normal sense of antigen presentation, due 
to the lack of a functional peptide transporter. Therefore, during pregnancy 
the developing fetus is protected from immunological attack potentially by 
both a physical barrier, such as negatively charged, sialic acid-rich 
mucopolysaccharide, and also an immunologically inert layer of placental 
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trophoblast tissue, on which MHC class I antigens are very weakly 
distributed and from which MHC class II molecules are absent. 
 
 
Figure 4. Diagrammatic representation of direct and indirect allorecognition In 
direct allorecognition pathway, intact donor Class-I and –II MHC molecules present on the 
surface of donor antigen presenting cell (APC) are recognized directly by recipient CD8+ 
and CD4+ T cells, respectively. In the indirect allorecognition pathway, donor Class-I and 
–II MHC molecules are taken up, processed and presented in the context of recipient 
MHC molecules to recipient CD8+ and CD4+ T cells, respectively. (Rogers and Lechler, 
American Journal of Transplantation, 2001). 
 
 
I.6. Embryonic stem (ES) cells 
Embryonic stem cells (ESCs) are derived from the inner cell mass of 
blastocysts (Evans et al. 1981; Martin 1981); (Thomson et al. 1998). 
Human ESCs are maintained in undifferentiated stage in the presence of 
basic fibroblasts growth factor (bFGF). The human ESC colonies have 
typical round shape compact morphology and cells express SSEA-4, Tra-
1-60 and Tra-1-81 pluripotent markers on their cell surface. They are 
passaged every 5-7 days either by mechanical cutting or by using 
collagenase IV or dispase in the form of small clumps. Single cell 
passaging of these ESCs can be done in presence of Rho kinase inhibitor 
(ROCKi), thiazovivin or neurotrophins using trypsin-EDTA (Pyle et al. 
2006; Watanabe et al. 2007). Murine ESCs are maintained in 
undifferentiated stage in the presence of LIF. In comparison to human 
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ESCs, the colonies are smaller in size having round or oval shape 
structures. They express SSEA-1 as pluripotency marker on their cell 
surface but not the SSEA4 or Tra antigens.They are passaged as single 
cells every 2-3 days using trypsin-EDTA. The characteristics of murine and 
human ESCs are summarized in Table 3. 
 
Table 3. Characteristics of murine and human ESCs 
 
Marker Mouse ESCs Human ESCs 
Oct-4 + + 
Alkaline 
Phosphatase 
+ + 
SSEA-1 + - 
SSEA-4 - + 
Tra-1-60 - + 
Tra-1-81 - + 
Telomerase 
activity 
+ + 
Factors aiding 
in self-renewal 
LIF+MEFs or LIF+gelatin-coated 
plastic 
MEFs+serum or MEFs+bFGF 
Morphology 
Tight, rounded, multilayer 
colonies, high nucleus to 
cytoplasm ratio 
Flatter colonies with tight border, 
high nucleus to cytoplasm ratio 
Rate of 
division 
Fast, passage every 2-3 days Slower, passage every 3-7 days 
Teratoma 
formation 
+ + 
Germ line 
competent 
+ Unknown 
 
Note: Presence (+) and absence (-), SSEA = stage specific embryonic antigen, LIF = 
leukemia inhibitory factor, bFGF = basic fibroblast growth factor; MEFs = murine 
embryonic fibroblasts. Table adapted from NIH Stem Cell report (NIH, 2006). 
 
 
I.7. Immunological properties of ES cells (ESCs) 
ESCs express MHC molecules on their cell surface but the constitutive 
expression of MHC I molecules as well as in their response to IFNγ differ 
greatly in human and murine ESCs. MHC class I molecules are present on 
the cell surface of undifferentiated human ESCs at low levels and are 
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inducible by IFNγ (Drukker et al. 2002; Grinnemo et al. 2006). There was 
no MHC induction by IFN-α and IFN-β due to the missing expression of 
these cytokine receptors on human ES cells (Drukker et al. 2002). On 
other side, the expression of MHC class I molecules was not detectable by 
flow cytometry on undifferentiated murine ES cells (Tian et al. 1997; 
Magliocca et al. 2006; Abdullah et al. 2007; Nussbaum et al. 2007). 
However, transcripts of MHC class I molecules, β2-microglobulin and 
several components of antigen presentation pathway were present in 
detectable amount in murine ESCs (Magliocca et al. 2006; Abdullah et al. 
2007). Using a highly sensitive and specific method for detection of rare 
peptide-MHC class I complexes utilizing the lacZ-inducible, antigen/MHC-
specific T cell hybridomas it was possible to provide the evidence that 
murine ES cells express MHC class I molecule but at very low levels that 
are not detectable by flow cytometry (Abdullah et al. 2007). The murine 
ESCs do not respond to IFN-γ and only after differentiation, they respond 
to IFNγ and strongly up regulate the expression of MHC class I molecules 
on a significant fraction of cells and components of antigen presenting 
pathway (Abdullah et al. 2007). Interestingly, MHC class II transcripts were 
present in human (Grinnemo et al. 2006) and murine (Magliocca et al. 
2006) ESCs that were inducible by IFNγ.  
Previous reports showed that murine as well as human ES cells may 
possess immune-privileged properties. Bonde and Zavazava have 
demonstrated that murine ESCs can not be lysed by naïve allogenic NK 
(Bonde et al. 2006) or polyI:C activated NK cells (Koch et al. 2008). 
However, other reports showed that murine ESCs can be lysed by NK 
cells in presence of IFNγ (Bonde and Zavazava 2006). The recognition of 
ESCs by NK cells appears to be mediated by ligands of activating natural-
killer group 2 member D (NKG2D) molecules and intercellular adhesion 
molecule-1 (ICAM-1) expressed on ESCs (Bonde et al. 2006; Frenzel et 
al. 2009). Human ES cells also showed limited lysis by NK cells possibly 
due to low expression of activating NK cell ligands such as NKp46 and 
CD16 on these ES cells (Drukker et al. 2002). Similarly, murine ES cells 
were not lysed by in vitro generated alloreactive CTLs (Bonde et al. 2006). 
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Additionally, lymphocytic choriomeningitis (LCM) virus-infected or peptide–
loaded murine ES cells were also resistant to killing by activated LCM 
virus-specific syngeneic CTLs (Abdullah et al. 2007). The expression of 
the granzyme B inhibitor serine protease inhibitor 6 (SPI-6) in 
undifferentiated murine ES cells appears to protect ESCs from CTL killing 
in vitro (Abdullah et al. 2007). This study also provided the evidence for 
functional recognition of ES cells by cytotoxic CD8+ T cells in vitro. Another 
study showed that ES cells suppress T cell proliferation in a contact-
independent manner by secreting TGF-β and expressing Fas-L on their 
surface to block alloreactive T cell apoptosis (Koch et al. 2008).  
Induced pluripotent stem cells (iPSCs) are ES-like cells made first time by 
retroviral reprogramming of murine somatic cells using combination of four 
transcription factors Oct3/4, Sox2, Klf4 and c-Myc (Takahashi et al. 2006). 
These iPSCs have highly similar transcriptional and epigenetic features to 
those of ESCs (Gupta et al. 2010; Takahashi et al. 2007; Wernig et al. 
2007; Yu et al. 2007). After this major findings, lot of different groups 
reprogrammed different murine and human somatic cells into iPSCs using 
viral and non-viral methods (Takahashi et al. 2007; Wernig et al. 2007; 
Stadtfeld et al. 2008; Kaji et al. 2009; Yu et al. 2009). In first stance, iPS 
technology opened new avenues for autologus transplantation but there 
are still lots of challenges of immunogenicity regarding the use of iPSCs 
and its derivatives in regenerative medicine. Additionally, researchers also 
found the epigenetic differences between ES and iPS cells (Kim et al. 
2010; Polo et al. 2010; Doi et al. 2009). 
A recent study demonstrated that few cells derived from iPSCs can be 
immunogeneic even in syngeneic settings (Zhao et al. 2011).This group 
reprogrammed C57BL6 (B6) mouse embryonic fibroblasts (MEFs) into 
iPSCs using either retroviral approach (ViPSCs) or an episomal approach 
(EiPSCs) that causes no permanent genomic integration of vector 
sequences. Later on, they transplanted B6 ESCs, ViPSCs and EiPSCs 
into the B6 recipients. Teratomas were formed by ESCs while teratomas 
formed by B6 ViPSCs were mostly immune-rejected by B6 recipients mice. 
Additionally, B6 EiPSCs teratomas were also immunogenic showing tissue 
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damage and regression with T cell infiltration. Since iPSCs and ESCs 
have shown to have subtle yet apparent epigenetic differences, this could 
be the basis for the expression of abnormal expression of antigens (minor 
antigens) on iPSCs but not on ESCs who have normal development and 
differentiation (Kim et al. 2010; Polo et al. 2010; Chin et al. 2009; Doi et al. 
2009). The expression of minor antigens on iPSCs makes them 
susceptible for T-dependent immune rejection. Moreover, iPSCs have 
shown mutations in their coding sequences that could further contribute to 
the immunogenicity of iPSCs derivetives (Gore et al. 2011). Recently, 
iPSCs have generated from patients with genetically inherited as well as 
sporadic diseases for in vitro disease modeling, gene corrections of 
defected gene and transplantation of corrected cell types to patients 
(Howden et al. 2011; Liu et al. 2011; Zou et al. 2011). However, successful 
replacement of cell types may elicit rejection of the grafted cells 
themselves enduring to recognition of the processed gene product in a 
MHC-restricted manner, likewise to recognition of minor histocompatibility 
antigens (Figure 5). To circumvent these limitations, one can capitalize the 
pluripotency of iPSCs to provide a source of immature dendritic cells 
(DCs) expressing the alloantigens to which tolerance is required (Fairchild 
2010).  
Pearl and coworkers reported that short time blockade treatment of 
costimulatory molecules is enough to induce engraftment of allogeneic 
mouse ESCs and iPSCs as well as xenogeneic human ESCs and iPSCs 
(Pearl et al. 2011). They showed that short term blockade of three 
costimulatory receptors: CTL-associated antigen 4 (CTLA4)-Ig, anti-CD40 
ligand (anti-CD40L), and anti-lymphocyte function-associated antigen 1 
(anti-LFA-1) - could induce long-term allogeneic and xenogeneic ESC 
engraftment by decreasing the expression of proinflammatory cytokines 
and increasing the establishment of a proapototic phenotype. These 
results indicated that short term blockade of costimulatorly molecules may 
also overcome the problem of minor histocompatibilty antigens in cellular 
engraftment of iPSCs. 
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Figure 5. Induction of tolerance to the products of corrected genes. “The generation 
of induced pluripotent stem cells (iPSCs) from individuals with diseases that are under 
monogenic control might enable correction of the genetic defect. Successful replacement 
of cell types in vivo could, however, induce neutralizing immune responses to products of 
the corrected gene or provoke rejection of the grafted cells themselves owing to 
recognition of the processed gene product in an MHC-restricted manner, similarly to the 
recognition of minor histocompatibility antigens. One approach to circumventing such 
immunogenicity might be the directed differentiation of immature dendritic cells (DCs) 
from the disease-corrected iPSCs, which endogenously express the gene product to 
which tolerance is required. Administration of such DCs in advance of cell replacement 
therapy in a non-inflammatory, tolerogenic context that does not promote DC maturation 
could enable the induction of a repertoire of regulatory T cells specific for the therapeutic 
gene product. Tolerance can subsequently be reinforced by the allograft itself, which 
functions as a continuous source of antigen”. (Fairchild,PJ, Nature Reviews Immunology, 
Dec. 2010). 
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II. Aims  
 
In mammals the expression of MHC genes are developmentally 
programmed. The MHC class I molecules play crucial role not only in 
fertilization and development of embryos but also in reinforcement of 
innate and adaptive immune responses against infectious agents or tumor 
cells. Since ESCs are excellent models to study development and 
differentiation into various types of cells, we used it to analyze the 
regulation of MHC class I molecules in these cells. Our group has 
previously shown that murine ESCs express very low levels of MHC class 
I molecules, which are not inducible by IFNγ. I, therefore, wished to 
investigate the reason of low expression of MHC class I molecules in 
ESCs and their unresponsiveness to IFNγ.  
The specific aims of this thesis are: 
1. To elucidate the mechanisms responsible for low expression of MHC 
class I molecules in undifferentiated murine ESCs 
2. To determine the mechanism for IFNγ unresponsiveness in ESCs. 
3. To determine whether same mechanisms are involved in regulation of 
expression of MHC class I molecules in differentiated cells 
4. To determine whether modulation of expression of MHC class I 
molecules affects the susceptibility of ESCs to immune cells in vitro. 
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III.  Results 
III.1. Regulation of MHC class I molecules in ESCs 
 
III.1.1. Expression of MHC class I molecules on ESCs 
Human and murine ESCs grow on feeders and need, respectively, bFGF 
or LIF as crucial additives in culture media to maintain their pluripotency. 
Human ESCs show typical flat, large and compact colony expressing Tra-
1-81 as a pluripotency marker on their surface (Figure 6A,B). Murine ESCs 
are round, oval shaped, smaller in size and express SSEA1 as a 
pluripotency marker on their surfaces (Figure 6C,D). 
 
         A.                                                    B. 
 
 
 
 
 
        C.                                                     D 
      
 
 
 
 
Figure 6. Characterization of human and murine ESCs. Typical morphology of human 
(A) and murine (C) ESCs. The expression of pluripotency markers Tra-1-81 (B) and 
SSEA1 (D) on human and murine ES cells, respectively, was determined by flow 
cytometry.  
 
 
To set conditions for our further mechanistic studies we used flow 
cytometry to determine expression of MHC class I molecules on ESCs and 
validate previously published results. We showed that human ESCs 
stained with pan-HLA-ABC antibodies W6/32 express MHC class I 
molecules on their surface (93.2% of positive cells, MFI=103.9) and that 
their expression is enhanced 7.8-fold after stimulation with IFNγ (98.4% of 
positive cells, MFI=812.3) (Figure 7A). In contrast, staining for H-2Kb MHC 
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class I molecules on two murine ESC lines (αPIG44 and CGR8) revealed 
that they were not detectable by flow cytometry and also not induced by 
IFNγ (Figure 7C). Same result was also obtained with murine induced 
pluripotent stem cell (iPSC) line AT25 (Figure 7C).  
 
  A.                                                          B. 
 
 
 
 
 
 
 
 
C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Expression of MHC class I molecules in murine and human ES cells and 
their regulation by IFNγ. Murine ES cells (αPIG44 and CGR8), murine iPS cells (AT25), 
human ES cells (HES2) and C57sv fibroblasts were cultured with or without 100 ng/ml 
IFNγ for 2 days. Cells were trypsinized and MHC class I molecules were analyzed using 
flow cytometry by acquiring 10,000 events. C57sv fibroblasts and murine ESCS/iPSCs 
were labeled with PE-conjugated anti-H-2Kb monoclonal antibody using PE-conjugated 
IgG2a antibody as isotype control (B,C). Human ES cells were labeled with primary pan-
HLA class I (W6/32) antibody and visualized with secondary anti-murine IgG-PE 
antibodies (A). Dead cells were excluded by gating or PI staining and histograms were 
generated by gating on viable cells.  
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In contrast to undifferentiated cells, ESCs and iPSCs undergoing 
differentiation in day 5 embryoid bodies (EBs) express flow cytometrically 
detectable levels of H-2Kb MHC class I molecules which were induced by 
IFNγ. αPIG44 ESC-, CGR8 ESC- and AT25 iPSC-derived EBs expressed 
H-2Kb molecules on 58.4% (MFI=35.1), 27.4% (MFI=32.1) and 23.3% 
(MFI=14.9) of cells, respectively. After stimulation with IFNγ these 
molecules were induced in these three cell lines by 9.7, 4.7- and 5.1-fold, 
respectively, increasing the percentage of positive cells to 89.0% 
(MFI=339.1), 88.8% (MFI=149.3) and 91.5% (MFI=76.1) (Figure 7C). For 
comparison, we also used as a positive control for expression of H-2Kb 
molecules the murine embryonic fibroblast cell line C57sv that was derived 
from C57BL/6 inbread mouse strain (MHC class I haplotype H-2Kb) and 
immortalized by stable expression of SV40 large T antigen. In these cells, 
H-2Kb molecules were constitutively expressed at very high levels (99.7% 
of positive cells, MFI=305) and were upregulated 7.9-fold after stimulation 
by IFNγ (99.6% of positive cells, MFI=2424) (Figure 7B). 
 
 
III.1.2. Expression of components of MHC class I processing 
machinery in ESCs and their differentiating derivatives  
MHC class I molecules are presented on the cell surfaces with the help of 
several components of the antigen processing and presentation pathway. 
The absence of any component of this pathway may result in reduced 
expression of these molecules on the cell surface and subsequent 
modulation of their recognition by CD8+ T cells or NK cells. To determine 
whether murine ESCs and day 5 EBs express the antigen presenting 
pathway components we determined the levels of transcripts encoding for 
MHC class I heavy (H-2Kb) and light (β2M) chain molecules, transporters 
associated with antigen processing (TAP)-1 and -2, as well as two 
immunoproteasomal subunits LMP2 and LMP7 by real-time PCR. The 
transcript for MHC class I heavy and light chain molecules were expressed 
at detectable levels in undifferentiated ES cells and day 5 EBs but this 
expression was two orders of magnitute lower compared to C57sv 
fibroblasts (Figure 8A). In agreement with flow cytometric analyses, these 
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transcripts were upregulated by IFNγ only in fibroblasts (2-fold for H-2Kb 
and 2-fold for β2M with a p<0.04) and day 5 EBs (9.6-fold for H-2Kb and 
4.5-fold for β2M with a p<0.001) but not in undifferentiated ESCs (1.1-fold 
for H-2Kb and 1.08-fold for β2M with p>0.39) (Figure 8A). The transcripts 
for TAP-1, TAP-2, LMP2 and LMP7 were present at transcript level in 
CGR8 ES cells as well as in day 5 EBs but they were only inducible by 
IFNγ in day 5 EBs (Figure 8B). Compared to fibroblasts, undifferentiated 
ESCs expressed lower levels of these transcripts and LMP7 was hardly 
detectable in untreated ESCs but was strongly induced by IFNγ (Figure 
8B). 
 
A.                                                   B. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Expression of MHC class I molecules and several components of antigen 
processing machinery. RNA was isolated from all the samples using Trizol method and 
cDNA was amplified from the same amount of RNA from all cell types with or without IFNγ 
treatment (100 ng/ml for 2 days). Real-time PCR analysis (A) showed the H-2Kb and β2M 
expression and induction by IFNγ in C57sv fibroblasts and ESC-derived day 5 EBs but 
very low expression and no induction in αPIG44 ESCs. Semiquantitative RT-PCR 
analysis of genes involved in MHC class I antigen presenting pathway. Data are given as 
mean ± s.e.m. of three replicates. These data are representative of three independent 
experiments. (B) In fibroblasts and CGR8 ESCs showed the expression of almost all 
analyzed genes (TAP1, TAP2, LMP7 and LMP2) in every cell type. However, a very low 
level of LMP7 was detected in CGR8 ES cells without IFNγ treatment. GAPDH gene used 
as endogenous control. 
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Comparing the data for MHC class I expression in C57sv fibroblasts at 
protein and transcript levels after IFNγ stimulation it is of note that the 
expression of MHC class I molecules on the cell surface is upregulated by 
IFNγ to a much higher extent (7.9-fold) than the expression of heavy and 
light chain transcripts (upregulation by only about 2-fold). However, in 
αPIG ESC-derived day 5 EBs IFNγ induced MHC class I expression at the 
protein and transcript level to a similar extent (9.7 vs 9.6 fold, 
respectively). This data indicate that different mechanisms regulate the 
extent of induction of MHC class I molecules on the surface of C57sv 
fibroblasts and day 5 EB cells by IFNγ and that stronger induction of MHC 
class I molecule expression at the protein than at the transcript level in 
fibroblasts but not in ESCs is presumably governed by other mechanisms 
(e.g. enhancement of MHC class I loading in the ER and transport to the 
cell surface).  
 
 
III.1.3. Expression of IFNγ receptors in ESCs and their differentiating 
derivatives 
IFNγ exerts its effect by interacting with the IFNγ-receptors (IFNGR) which 
are present on the surfaces of nearly all cells and leads to the downstream 
signaling activating IFNγ-inducible genes. We next assessed whether the 
lack of murine ESCs to respond to IFNγ was due to absence of IFNGR on 
their cell surface. The expression of IFNγ-R1 (αR) was determined at the 
transcript and protein level in undifferentiated ESCs, differentiated day 6 
EBs and C57sv fibroblasts cultured with and without IFNγ (100 ng/ml) for 2 
days). At the transcript level, the IFNγ-R1(αR) was expressed in C57sv 
fibroblasts, CGR8 ESCs and day 6 EBs at similar levels (Figure 9A). 
These transcripts were induced by IFNγ in fibroblasts and EBs but not in 
the ESCs. Flow cytometric analysis revealed that IFNγ-αR and IFNγ-βR 
subunits are equally expressed in undifferentiated ESCs as well as in 
differentiating day 5 EBs (Figure 9B). The expression of IFNGR was 
reduced by IFNγ treatment on both ES and EB cells, presumably as a 
consequence of receptor downregulation (Figure 9B). These data indicate 
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that the inability of ESCs to upregulate MHC class I expression after IFNγ 
stimulation is not due to missing expression of IFNGR on their surface.  
A. 
 
 
 
 
 
B.  
 
 
 
 
 
 
 
 
Figure 9: Expression of IFNγ receptors in undifferentiated and differentiated ES 
cells. A. The expression of IFNγ-R1 in fibroblasts, CGR8 ES cells and day 6 EBs was 
determined by semiquantitative RT-PCR analysis (product size = 208 nt). GAPDH was 
used as housekeeping gene in this analysis (product size = 111). B. Flow cytometry was 
done to determine the protein level expression of IFNγ-αR and IFNγ-βR in αPIG-ESCs 
and ESC-derived EBs in the presence and absence of IFNγ (100 ng/ml for 2 days). Cells 
were dissociated by trypsin-EDTA and stained with monoclonal antibodies specific for 
IFNγ-αR (Isotype Rat IgG2a) and IFNγ-βR (Isotype ArmHam IgG). 
 
 
III.1.4. Expression and activity of STAT1 in ESCs 
The biological actions of IFNγ are mediated through the STAT1 signaling 
cascade. Binding of IFNγ to IFNGR induces activation of receptor complex 
which leads to the transphosphorylation of Janus-activated kinases 1 and 
2 (JAK1, JAK2) that, in turn, phosphorylate STAT1 at tyrosine residue 701. 
Activated STAT1 dimerizes and translocates into the nucleus to induce the 
expression of IFNγ-inducible genes. Therefore, we asked whether lack of 
STAT1 expression or phosphorylation in ESCs may be the reason for their 
unresponsiveness to IFNγ. Real-time PCR analyses revealed that STAT1 
transcripts were expressed at much lower levels in ESCs (relative 
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expression=1) and day 5 EBs (relative expression=1.08) as compared to 
fibroblasts (relative expression=20.9) (Figure 10A). STAT1 transcripts 
were upregulated by IFNγ only in fibroblasts (3.5-fold, p<0.005) and day 5 
EBs (20-fold, p<0.001) but not in undifferentiated ESCs (1.4-fold, p<0.19), 
which is in agreement with data obtained for MHC class I molecules and 
other genes in this study.  
 
 
A.  
 
 
 
 
 
 
 
 
 
 
 
 
 
B.  
 
 
 
 
 
 
 
 
 
Figure 10: Expression of STAT1 at transcript and protein level in ESCs and EBs.  A. 
C57sv fibroblasts, CGR8 ES cells and day 5 EBs were cultured with or without IFNγ (100 
ng/ml for two days) and the STAT1 gene expression was determined by real-time PCR. 
The STAT1 expression in each sample was normalized with the housekeeping gene 
GAPDH. Data are presented by assigning the expression value of 1 to ESCs. Data were 
statistically analyzed using Student’s t-test. Data are given as mean ± s.e.m. of three 
replicates. These data are representative of two independent experiments. B. C57sv 
fibroblasts, CGR8 ES cells and day 5 EBs were treated with or without IFNγ (100 ng/ml 
for 15 minutes) and the same amount of protein (15 μg) was loaded for each sample for 
analysis of total STAT1 and STAT1 phophorylated at tyrosine residue 701 by 
immunoblotting. The signal was visualized using alkaline phosphatase-based 
chemiluminescence detection system.  
 
 
In agreement with the STAT1 transcript levels, the total STAT1 protein 
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and EBs (Figure 10B). In the absence of IFNγ the amount of STAT1 in 
ESCs and EBs was comparable. In the presence of IFNγ the total STAT1 
protein levels did not change in IFNγ-treated ESCs but, surprisingly, also in 
IFNγ-treated EBs. This was not expected because the expression of 
STAT1 transcripts was strongly upregulated by IFNγ in EBs (see Figure 
10A). Without IFNγ, STAT1 was not phosphorylated in any cell type 
analyzed (Figure 10B, left panel). IFNγ treatment induced strong 
phosphorylation of STAT1 only in C57sv fibroblasts but not in ES cells and 
day 5 EBs (Figure 10B, right panel). The inability to detect phosphorylated 
STAT1 in ESCs and EBs might be due to low expression levels of this 
protein in these cells. Therefore, with this method it is not possible to 
assess whether ESCs and EBs exhibit any differential STAT1 
phosphorylation, which could explain the differences in MHC class I 
induction by IFNγ in these cells.  
 
 
III.1.5. Expression of regulatory components of STAT1 signaling 
pathway and their activation by IFNγ in murine ESCs  
The activity of the STAT1 signaling pathway is also regulated by other 
components of this pathway such as obove mentioned kinases JAK1 and 
JAK2 as well as regulators such as suppressor of cytokine signaling 1 
(SOCS1), non-receptor type protein tyrosine phosphatase PTP1B 
(encoded by PTPN1) and Src homology region 2 domain-containing 
phosphatases 1 and 2 (SHP-1 and SHP-2 encoded by PTPN6 and 
PTPN11 genes, respectively). SHP-1 enhances STAT1 activation while 
SHP-2, PTP1B and SOCS1 negatively regulate STAT1 activation. The 
transactivating activity of STAT1 dimers is also regulated by their import 
from the cytosol into the nucleus through importin α. Since all these 
components of STAT1 signaling pathway are important for its proper 
activity, we checked the transcript level expression of these genes in 
C57sv fibroblasts, murine CGR8 ESCs and day 5 EBs. JAK1, JAK2, 
SOCS1, PTP1B, SHP-1 and SHP-2 were expressed at similar levels in all 
analyzed cells both in the presence and absence of IFNγ (Figure 11A). 
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IFNγ upregulated only the expression of JAK2 and SOCS1 in C57sv 
fibroblasts and day 5 EBs but not in ESCs further confirming our finding of 
unresponsiveness of ESCs to IFNγ. 
 
 
A.                                                            B. 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 11. Expression of components related to STAT1 signaling pathway in 
murine ES cells. A. Expression of JAK1, JAK2, SOCS1, PTP1B, SHP1, SHP2, IRF1 and 
IRF2 transcripts as determined by semiquantitative RT-PCR analysis in C57sv fibroblasts, 
CGR8 ESCs and day 5 EBs. B. Expression of transcripts encoding for importin subunits 
Kpna1, Kpna2, Kpna6 and Kpnb in the same cell lines. 
 
 
The IFNγ regulatory factors 1 and 2 (encoded by IRF1 and IRF2 genes, 
respectively) mediate transcriptional effects of IFNγ in STAT1 dependent 
or independent manner depending on a target gene. IRF-1 generally 
functions as a transcriptional activator or repressor of a variety of target 
genes that are activated by type I IFN signaling, while IRF2 is a 
transcriptional suppressor that competitively inhibits the IRF1-mediated 
transcriptional activity. IRF1 transcripts were expressed in ESCs and day 5 
EBs at the same level as in C57sv fibroblasts but IFNγ induced the IRF1 
expression only in fibroblasts and EBs (Figure 11A). IRF2 transcripts were 
expressed in day 5 EBs and fibroblasts at comparable levels and were not 
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regulated by IFNγ. Interestingly, IRF2 transcripts were not detectable in 
ESCs both in the presence or absence of IFNγ (Figure 11A). Absence of 
IRF2 in ESCs could be one of the reasons for unresponsiveness of ESCs 
to IFNγ (Rouyez et al. 2005). 
The importins play a crucial role in the nuclear localization of activated 
STAT1 inside the nucleus to induce IFNγ regulated genes. The importin 
subunits α-5, α-1, α-6 (also known as karyopherin α-1, α-2, α-6) are 
encoded by genes KPNA1 and KPNA2, KPNA6 respectively. The importin 
subunit β (also known as karyopherin β) is encoded by gene KPNB. 
Activated STAT1 goes into the nucleus by importin-α5 (KPNA1) with the 
help of importin-β (KPNB) and it was previously reported that importin-α1 
(KPNA2) switches to importin-α5 when ESCs differentiate. The KPNA1 
and KPNB were expressed in ESCs at  levels similar to those in fibroblasts 
and day 5EBs. None of these genes was inducible by IFNγ in any of the 
cell lines tested (Figure 11B). These data suggest that the inability of IFNγ 
to induce the expression of IFNγ responsive genes in ESCs may not be 
due to lack of translocation of STAT1 dimers to the nucleus.  
 
 
III.1.6. The role of LIF in control of MHC class I expression in murine 
ESCs and its derivatives 
Pluripotency of murine ESCs is maintained by LIF, which is the standard 
component of murine, but not human ESC culture media. Therefore, we 
tested if LIF is responsible for low expression levels of MHC class I 
molecules on murine ES cells as compared to their human counterparts. In 
addition, we were interested in determining if LIF signaling through STAT3 
pathway interferes with the activation of STAT1 pathway by IFNγ and in 
this way negatively affects the induction of MHC class I expression in 
murine ESCs. To test this hypothesis, ESCs were first cultured with or 
without LIF in the presence or absence of IFNγ and H-2Kb expression was 
measured by flow cytometry after 48 h of treatment. These analyses 
revealed that in the absence of IFNγ transient LIF removal for 2 days did 
not increase the expression of H-2Kb molecules on ESCs (Figure 12A). 
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IFNγ treatment of ESCs cultured in the absence of LIF only insignificantly 
enhanced the expression of these molecules (9.1% positive cells with LIF, 
MFI=52; 18.6% of positive cells without LIF, MFI= 61.3) (Figure 12B).  
 
 
 
 
 
 
 
 
Figure 12. Regulation of MHC class I expression on murine ES cells (A,B) and EBs 
(C,D) by LIF in the presence and absence of IFNγ. αPIG ES cells were cultured for two 
days with or without IFNγ and/or LIF and the expression of H-2Kb molecules was 
determined by flow cytometry (A,B). To test the effect of LIF on MHC class I expression 
on differentiating cells, the formation of EBs was initiated for three days without LIF. LIF 
was then added to day 3 EBs for additional 2 days in the presence or absence of 100 
ng/ml IFNγ and the expression of H-2Kb molecules was determined in EBs on day 5 of 
differentiation (C,D). For each sample 10000 events were acquired and all analyses were 
done by gating on viable cells. 
 
The failure to detect a major effect of LIF on MHC class I expression in 
undifferentiated ES cells could be due to incomplete inactivation of LIF 
signaling pathway under these culture conditions. Therefore, ES cells that 
were differentiated to EBs in the absence of LIF for 5 days may represent 
more appropriate model to investigate the role of LIF in regulating the 
expression of MHC class I molecules, because the LIF pathway may be 
sufficiently inactivated under these conditions. To this end, we have first 
induced the differentiation of ES cells by allowing formation of EBs without 
LIF for 3 days. At day 3 of differentiation, the EBs were then divided into 
two groups, which were cultured for additional two days, one without and 
another with LIF. The expression of H-2Kb molecules was determined at 
day 5 of differentiation by flow cytometry. As already shown in Figure 7C, 
cells in day 5 EBs differentiated without LIF expressed high amounts of 
MHC class I molecules on their cell surface (68.9% of positive cells, 
MFI=30.9) and their levels were upregulated 3.7-fold (in reference to MFI) 
by IFNγ increasing the fraction of positive cells to 84.2% and MFI to 115.3 
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treated with LIF in the absence of IFNγ showed expression of MHC class I 
molecules only on 26.2% cells (MFI=46), which represents a 2.6-fold 
reduction in reference to % positive cells cultured in the absence of LIF 
(Figure 12C). In addition, LIF also strongly reduced the expression of MHC 
class I molecules in EBs treated with IFNγ (42.3% of positive cells, 
MFI=95.4) (2-fold reduction in reference to positive cells without LIF) 
(Figure 12D). Interestingly, H-2Kb expressing day 5 EBs maintained the 
same MFI value even in the presence of LIF, indicating that LIF completely 
abrogated the MHC class I expression rather than simply decreased their 
levels on the surface of these cells. Since LIF mediates its effects through 
STAT3 pathway, these data indicate that LIF/STAT3 signaling may play a 
negative role in regulating MHC class I molecules not only in EBs but also 
in undifferentiated murine ES cells.  
 
 
III.1.7. The role of STAT3 in regulation of MHC class I molecules in 
undifferentiated ESCs 
The LIF removal experiments with EBs provided strong indication that 
LIF/STAT3 pathway may play an important role in keeping the expression 
of MHC class I molecules in ESCs at low levels and preventing their 
induction by IFNγ. In order to provide additional evidence for the role of 
this pathway in control of MHC class I expression in undifferentiated 
ESCs, we used STAT3-specific small interfering RNAs (STAT3 siRNA) to 
transiently downregulate the expression of STAT3 in these cells.  
 
III.1.7.1. Validation of STAT3 knockdown (KD) by siRNA 
To validate the efficiency of transfection of ES cells with siRNA, we used 
control scrambled siRNA conjugated to AlexaFLour 647 (siRNA647). 
Flourescence microscopy of these cells one day after lipofection showed 
that the great majority of cells were efficiently labeled by these molecules 
(Figure 13A). In the next step, the optimal siRNA concentration required 
for maximal STAT3 KD was determined. To this end, ES cells were treated 
for 48 h with different concentrations of STAT3-siRNA or control 
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scrambled siRNA647 and STAT3 transcript levels were analyzed by real-
time PCR and immunoblotting. Compared to control cells, STAT3 mRNA 
expression in ES cells treated with STAT3-siRNA was reduced by up to 
80-90% at all used STAT3-siRNA concentrations (Figure 13B).  
 
A. 
 
 
 
 
 
B.  
 
 
 
 
 
 
C.  
 
 
 
 
Figure 13: The validation of transient STAT3 KD in murine ES cells. A. Murine ESCs 
were transfected with 20 nM scrambled siRNA conjugated to AlexaFluor 647 (yellow) for 
2 days. Merged image showed successful transfection of siRNA647 into murine CGR8 
ESCs.. B. RNA was isolated from STAT3 KD and control murine ES cells. Real time PCR 
was performed using SybrGreen and primers for STAT3 and STAT1. GAPDH was used 
as endogenous control. Data are given as mean ± s.e.m. of three replicates. These data 
are representative of two independent experiments. C. Validation of STAT3 KD by 
immunoblotting. The same amount of protein (15 μg) was loaded for immunoblot analysis. 
STAT3 polyclonal antibody was used to detect the protein level expression and β-actin 
antibody was used as housekeeping control. 
 
In contrast, the expression of STAT1 transcripts was enhanced both in 
siRNA647 and STAT3 siRNA treated ESCs as compared to untreated 
cells, suggesting a non-specific and concentration independent effect of 
siRNA treatment on expression of this gene in ESCs. The immunoblot 
Transmission image siRNA 647 Merged image
0
1
2
3
4
5
1
R
el
at
iv
e 
ex
pr
es
si
on STAT3 
No s
iRN
A
100
nM 5nM 20n
M
100
nM
Control siRNA 647 STAT3 siRNA
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1
STAT1 
R
el
at
iv
e 
ex
pr
es
si
on
No s
iRN
A
100
nM 5nM 20n
M
100
nM
Control siRNA 647 STAT3 siRNA
R
el
at
iv
e 
ex
pr
es
si
on
R
el
at
iv
e 
ex
pr
es
si
on
STAT3
β-actin
Cntrl 100nM 5nM 100nM20nM
STAT3 siRNAsiRNA647
 49
analysis showed that STAT3 protein level was strongly dowregulated in 
STAT3 siRNA treated ESCs at all concentrations used and was not 
affected by siRNA647 compared to untreated control (Figure 13C). For all 
further knock down experiments we used both siRNAs at the concentration 
of 20 nM. 
 
 
III.1.7.2. STAT3 KD ESCs maintain expression of pluripotency 
markers 
Since LIF/STAT3 plays a major role in keeping undifferentiated state of 
ESCs, it was essential to determine whether the pluripotency of ESCs was 
affected by transient STAT3 KD. If STAT3 KD also stimulated the 
differentiation of ESCs, it would be more difficult to discern whether STAT3 
KD itself or other processes induced by differentiation are responsible for 
upregulation of MHC class I molecules in these cells. Semiquantitative RT-
PCR analysis showed that the core pluripotency genes Sox2, Nanog and 
Oct4 were expressed at similar levels in control and STAT3 KD murine ES 
cells (Figure 14A). Quantitative RT-PCR assessment of Oct4 and Nanog 
mRNA expression confirmed these data (Figure 14B). Another marker, the 
T-box transcription factor 3 (Tbx3), which maintains pluripotency of ES 
cells by PI(3)K pathway, was also not affected by transient STAT3 
downregulation. However, the expression of Krueppel-like factor 4 (Klf4), 
which is directly regulated by LIF/STAT3 pathway, was significantly 
reduced in STAT3 KD ES cells (Figure 14B). In addition, cell surface 
marker of pluripotent murine ESCs SSEA-1 was also expressed at similar 
levels on both cell populations (Figure 14C). Collectively, these data 
suggest that STAT3 KD ESCs remain in their undifferentiated state despite 
the transient reduction of STAT3 levels. This may be possible because LIF 
signals to the core circulatory network of pluripotency not only through the 
STAT3/Klf4 but also the PI(3)K/Tbx3 pathway (Niwa H et al 2009), which 
was not affected by out experimental conditions. 
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III.1.7.3. STAT3 KD ESCs form teratomas at the same kinetics as 
control cells 
Undifferentiated ESCs routinely develop into teratomas when injected into 
different anatomical sites of syngeneic or immunodeficient recepients. 
Teratoma formation by ESCs is another important proof to show ES cell’s 
pluripotency and is an essential part of a routine quality control of ES cells 
propagated in cell culture. Therefore, in order to provide further evidence 
for the pluripotency of STAT3 KD ESCs we injected one million of control 
siRNA- and STAT3 siRNA-treated ESCs subcutaneously into scapular  
      A.                                         B.                                               
 
 
 
 
 
 
 
 
C. 
 
 
 
 
 
 
 
Figure 14: STAT3 KD murine ES cells maintain their pluripotency.RNA was isolated 
from controls and STAT3 KD ES cells. Pluripotency markers Oct4, Nanog, Sox2, Klf4 and 
Tbx3 were measured by RT-PCR and real time PCR analysis in control and STAT3 KD 
ES cells. A. RT-PCR analysis showed similar expression levels of Oct4, Sox2 and Nanog 
in control and STAT3 KD ESCs. Data are given as mean ± s.e.m. of three replicates. 
These data are representative of two independent experiments. B. Expression of Oct4, 
Nanog and Tbx3 were not changed (p-value> 0.05) while expression of Klf4 was changed 
significantly in STAT3 KD ES cells in comparison to controls (p< 0.05)..C. The expression 
of SSEA-1 pluripotency marker as determined by flow cytometry on control and STAT3 
KD ES cells.  
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region of immunodeficient Rag2-/-γc-/- mice and teratoma growth was 
measured over the period of one month. No significant difference was 
observed in the growth kinetics of teratoma derived by control and STAT3 
siRNA-treated αPIG ESCs (Figure 15). Taken together, these results 
confirmed that transient STAT3 KD doesn’t affect the pluripotency of 
murine ESCs and that the upregulation of MHC class I molecules on 
STAT3 siRNA-treated ESCs can be attributed to direct effect of STAT3 
and not other processes that may be induced by differentiation of these 
cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Teratoma growth kinetics of STAT3 KD and siRNA647 control αPIG ES 
cells. ESCs (1x 106 cells) were injected subcutaneously into immunodeficient Rag2-/-γc-/-
mice (N=3). In every mouse, both types of KD cells were injected into each side. The size 
of teratomas was measured every week up to 1 month. In all time points, no significant 
difference in growth kinetics were observed (p>0.1). 
 
III.1.7.4. Effect of PI(3)K-inhibition on pluripotency of STAT3 KD ESCs 
LIF acts through STAT3 and PI(3)K pathways and maintains the 
pluripotency of murine ESCs. Since STAT3 KD murine ESCs retained their 
pluripotency, we asked whether inhibition of PI(3)K pathway would 
compromise the expression of core pluripotency markers in ESCs so as to 
provide the indirect evidence for our notion that STAT3 KD ESCs maintain 
pluripotency througt this pathway. 
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To this end, STAT3 KD ESCs were treated with PI(3)K inhibitor LY294002. 
for 48 h and the expression of pluripotency markers Oct4 and Nanog was 
determined by quantitative RT-PCR. As compare to control and siRNA 647 
treated ESCs, OCT4 expression was maintained but NANOG expression 
was down regulated significantly in LY294002 treated STAT3 KD ESCs 
(Figure 16). This data is in agreement with the fact that NANOG is a direct 
target of PI(3)K pathway. The maintenance of Oct4 expression in LY94002 
treated STAT3 KD ESCs might be due to incomplete inhibition of STAT3 
and PI(3)K pathways or other mechanisms. This data suggest that the 
activation of the PI(3)K pathway and Nanog by LIF at least partially 
supports the undifferentiated state in STAT3 KD ESCs.  
 
 
 
 
 
 
 
 
 
 
Figure 16. Effect of pluripotency in LY294002 treated STAT3 KD αPIG44 ES cells 
STAT3 KD αPIG ES cells were treated with 10 μM of PI(3)K inhibitor LY294002 for 48 h. 
Oct4 and Nanog mRNA expression was determined by real-time PCR using SyberGreen 
dye. GAPDH was used as endogenous control. LY294002 treated STAT3 KD ES cells 
showed down regulation of Nanog (p<0.05) while Oct4 mRNA expression was affected 
neither by STAT3 KD nor by LY294002 (p>0.05). Black columns represent the treatment 
of PI(3)K inhibitor LY294002 while white columns represent no treatment of this inhibitor. 
Data are given as mean ± s.e.m. of three replicates. These data are representative of 
three independent experiments. 
 
III.1.7.5. STAT3 KD leads to induction of H-2Kb molecules in ESCs 
The analyses described above strongly suggest that the inability to induce 
H-2Kb molecules by IFNγ in murine ESCs might be due to active 
LIF/STAT3 pathway. To determine if this is the case, STAT3 gene was 
transiently downregulated in ES cells, which were cultured either in the 
presence or absence of IFNγ. Using real-time PCR analysis we found that 
in comparison to no-siRNA- and scrambled siRNA-treated cells, the 
STAT3 KD significantly increased the levels of H-2Kb and β2M transcripts 
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both in IFNγ-untreated and IFNγ-treated cells (Figure 17A). Compared to 
control siRNA treated cells, STAT3 KD increased the expression of MHC 
class I α and β chain mRNAs in IFNγ-treated cells, respectively, by 1.9- 
and 1.6-fold, and in IFNγ-treated cells by 2.4- and 2.5-fold (Figure 17A).  
 
A. 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Transient STAT3 KD leads to the induction of H-2Kb in murine ESCs. A. 
The expression of H-2Kb  and β2M at transcript level was determined by real time PCR in 
in control and STAT3 KD CGR8 ESCs cultured in the presence or absence of IFNγ (100 
ng/ml). GAPDH gene was used as internal control and the expression in control ESCs 
was set at value of 1. Data are given as mean ± s.e.m. of three replicates. These data are 
representative of three independent experiments. B. The expression of H-2Kb molecules 
on αPIG and CGR8 ESCs and AT25 iPSCs was determined by flow cytometry. Cells 
were treated for 2 days (100 ng/ml) with or without IFNγ and indicated siRNAs. Cells were 
stained with the indicated antibodies or with the corresponding isotype controls (gray 
shaded histograms). All histograms were generated by gating on viable cells.  
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To determine whether the STAT3 KD mediated increase of H-2Kb and β2M 
transcript levels also lead to higher expression of mature MHC class I 
molecules on the cell surface, STAT3 KD ES cells were stained with 
monoclonal antibody specific for H-2Kb molecules and analyzed by flow 
cytometry. STAT3 KD increased the fraction of H-2Kb-positive αPIG ESCs 
5.9-fold to 23.6% (MFI=19.3) as compared to control siRNA treatment 
yielding only 4.0% positive cells (MFI=13.2) (Figure 17B, top row). 
Importantly, the fraction of H-2Kb–positive ESCs further increased to 
62.0% (MFI=41.1) by treatment with IFNγ. 
STAT3 KD CGR8 ESCs also increased 2.7-fold the fraction of H-2Kb 
positive cells (11%, MFI=10.7) as compared to control siRNA647-treated 
cells (4%, MFI= 10.5) (Figure 17B, middle row). Like in αPIG ESCs, the H-
2Kb expression was further induced on 42.8% of CGR8 ESCs (MFI=23.7) 
by treatment with IFNγ. Additionally, STAT3 KD AT25 iPSCs also showed 
24.4% enhancement of H-2Kb positive cells (MFI=26.6) as compared to 
control si RNA 647 treated cells (5.6% positive cells with MFI= 44), and 
this was further increased by addition of IFNγ (46.3%, MFI=41.4). No 
change in H-2Kb expression was observed in control or scrambled siRNA-
treated iPSCs (Figure 17B, bottom row). These analyses clearly 
demonstrate that STAT3 plays an important role in regulation of H-2Kb 
molecules in ES and iPS cells and both in the presence and absence of 
IFNγ.  
 
III.1.7.6. STAT3 KD enhances STAT1 activity in IFNγ treated and 
untreated ESCs 
IFNγ is a chief cytokine that phosphorylates STAT1 leading to its 
dimerization, translocation into the nucleus and the activation of a number 
of IFNγ inducible genes including the MHC class I α and β molecules. 
Transcriptionally active STAT1 dimers recognize specific DNA sequences, 
called Interferon-Gamma Activated Sites (GAS), in promoter regions of 
Interferon Stimultaed Genes (ISGs). To determine the transcriptional 
activity of STAT1, we performed the dual luciferase reporter assay system 
where we transiently co-transfected the firefly and renilla luciferase vectors 
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into C57sv fibroblasts, and control and STAT3 KD αPIG and CGR8 ESCs. 
Firefly luciferase activity (encoded by luc gene) was under the control of 
GAS promoter while constitutive renilla luciferase activity (encoded by 
hRluc gene), was under the control of ubiquitious CMV promoter used as 
internal control. 
A. 
 
 
 
 
 
 
 
 
 
 
 
B. 
 
 
 
 
 
Figure 18. Effect of STAT3 KD on transcriptional activity and phosphorylation of 
STAT1 gene in murine ESCs. A. Luciferase reporter assay was performed using IFNγ 
responsive GAS element. The C57sv fibroblasts and ESCs were transiently transfected 
with vectors in which firefly luciferase was under the control of GAS promoter and renilla 
firefly luciferase under the control of CMV promoter. In parallel, cells were treated with or 
without indicated siRNAs After 48hrs, the ESCs were treated with 100 ng/ml IFNγ for 6 
hrs and the luciferase activity was measured in luminometer. .The asterisk (*) indicates a 
p value < 0.01 and asterisks (**) indicate a p-value< 0.001. Data are given as mean ± 
s.e.m. of three replicates. B. Intracellular staining was used to detect the phosphorylation 
of STAT1 at the tyrosine residue 701 in C57sv fibroblasts, control and STAT3KD ESCs. 
Cells were fixed in cold methanol, stained with phopho-STAT1 antibody conjugated to 
AlexaFluor488 and measured by flow cytometry.  
 
In C57sv fibroblasts, that were used as our reference cell line, IFNγ  
induced 17.3-fold the low constitutive transcriptional activity of STAT1 by 
increasing the luminescence intensity from 8.1 relative luminescence units 
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(RLU), in untreated cells to 139.8 RLU in IFNγ-treated cells (n=3, p<0.001) 
(Figure 18A).  
In IFNγ-untreated control ESCs, the transcriptional activity of STAT1 was 
very low (o.38 RLU in αPIG ESCs and 1.6 RLU in CGR8 ESCs) (Figure 
18A). STAT3 KD slightly increased its transcriptional activity by about 2-
fold (1.1 RLU in αPIG ESCs and 3.8 RLU in CGR8 ESCs). However, in 
IFNγ-treated STAT3 KD αPIG and CGR8 ESCs the STAT1 was 
trancriptionally more active reaching the values similar to those measured 
in siRNA- and IFNγ-untreated C57sv fibroblasts (6.8 RLU in αPIG and 8.3 
RLU in CGR8 ESCs as compared to 8.1 RLU in C57sv fibroblasts) (Figure 
18A). In untreated or siRNA647-treated control cells IFNγ enhanced the 
binding of STAT1 to GAS (2.5 RLU in siRNA647 treated αPIG ESCs and 
3.3 RLU in CGR8 ESCs, p<0.01), but this was presumably not sufficient 
for any significant induction of H-2Kb molecules on the cell surface 
(compare to Figure 17B). These data demonstrate that STAT3 is an 
important regulator of STAT1 transcriptional activity in ESCs and that 
STAT3 in ESCs prevents, at least in part, the induction of MHC class I 
molecules by IFNγ by blocking STAT1 activation.  
To provide experimental evidence for this conclusion, we used flow 
cytometry to measure the phosphorylation of STAT1 at residue 701 in our 
cell lines after short exposure to IFNγ. We found that STAT1 was 
phosphorylated only in IFNγ-treated C57sv fibroblasts (MFI=11.1) but not 
in untreated cells (MFI=1.1) (Figure 18B). In agrrement with our luciferase 
reporter assay, STAT3 KD led to the STAT1 phosphorylation in IFNγ-
treated αPIG ESCs (MFI=0.6) and CGR8 ESCs (MFI=1.1) but not in IFNγ-
untreated αPIG ESCs (MFI=0) and CGR8 ESCs (MFI=0.8) (Figure 18B). 
In conclusion, these results indicate that STAT3 signaling has negative 
impact on STAT1 activity thus preventing the efficient induction of MHC 
class I molecules by IFNγ. 
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III.1.7.7. STAT3 KD downregulates the expression of suppressor of 
cytokine signaling 3 (SOCS3) in ESCs 
The members of the suppressor of cytokine signaling (SOCS) family play 
an important role in regulating the activity of STATs. SOCS1 negatively 
regulates the STAT1 while SOCS3 negatively regulates the STAT3. It was 
previously reported that STAT3 induced SOCS3 plays negative role in the 
activation of STAT1 (Hong et al. 2002). Therefore, we used quantitative 
RT-PCR to determine if STAT3 KD affects SOCS1 and SOCS3 mRNA 
levels in ESCs. SOCS1 mRNA expression was reduced by 33% without 
statistical significance (p<0.06, n=3). In contrast, SOCS3 mRNA 
expression was statistically significantly downregulated in STAT3 KD 
ESCs by 50% (p<0.05, n=3) (Figure 19). These findings raise the 
possibility that blockade of STAT1 phosphorylation by STAT3 is mediated 
by SOCS3 in murine ESCs. 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Effect of STAT3 KD on expression of suppressor of cytokine signaling -1 
and 3 (SOCS1 and 3) mRNAs in murine CGR8 ESCs. The expression of SOCS1 and 
SOCS3 transcripts was determined by real time RT-PCR. SOCS3 mRNA was 
significantly downregulated (p<0.05, n=3) while SOCS1 was not significantly changed in 
STAT3 depleted ES cells (p>0.05, n=3, number of independent experiments =2).  Data 
are given as mean ± s.e.m. of three replicates.  
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III.2.    Epigenetic regulation of MHC class I molecules in 
murine ESCs 
 
The downregulation of STAT3 leads to increase of MHC class I expression 
also in the absence of IFNγ. Therefore, this effect of STAT3 is not 
mediated through STAT1 signaling, but rather through direct effect of 
STAT3 on transcription of genes for MHC class I molecules or genes 
encoding epigenetic modifiers, which then indirectly effect the expression 
of MHC class I (Suarez-Alvarez et al. 2010). Therefore, we decided to 
check the expression of epigenetic modifier genes in STAT3 KD ESCs and 
the expression level of MHC class I molecules and their response to IFNγ 
in Dnmt KO ESCs. Addtionally, the effect of 2,5-aza and TSA (potent 
epigenetic modifiers) were checked on the expression of MHC class I 
molecules and their response to IFNγ in murine ESCs. 
 
III.2.1. STAT3 regulates the expression of epigenetic modifier genes 
in ESCs 
Dnamt1 is the most abundant methyltransferase in mammals and plays a 
major role in establishment and regulation of tissue specific patterns of 
methylated cytosines residues. Eed1 is a member of polycomb (PcG) 
protein family. It interacts with two other proteins (immunodeficiency virus 
type 1 (HIV-1) protein and histone deacetylase proteins). This complex 
serves as a platform to recruit DNA methyltransferases. JmjD1 is a 
jumonji-domain containing protein which encodes lysine-specific 
demethylase. This enzyme is supposed to be involved in posttranslational 
histone modifications. 
Since Dnamt1, Eed1 and JmjD1 are target genes of STAT3 (Zhang et al. 
2006; Ura et al. 2008; Bourillot et al. 2009), we asked whether their 
expression in ESCs was affected by transient STAT3 KD. Dnamt1, Eed1 
and JmjD1 mRNAs were all expressed at lower levels in STAT3 KD ES 
cells. However, only Eed1 was significantly downregulated in comparison 
to control ESCs (Figure 20). This data suggests that in ESCs STAT3 
maintains the promoter regions of MHC class I α and β chain genes in 
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highly methylated state through recruitment of DNA methyltransferases 
thus preventing their efficient transcription. 
 
 
 
 
 
 
 
 
 
 
Figure 20. Expression of epigenetic modifiers in STAT3 KD ES cells. RNA was 
isolated from controls and STAT3 KD CGR8 ES cells and cDNA was amplified with the 
same amount of RNA. Real time PCR analysis was performed using primers specific for 
indicated genes. Data are given as mean ± s.e.m. of three replicates. These data are 
representative of two independent experiments. 
 
 
III.2.2. Dnamt knockout murine ES cell lines show enhanced MHC 
class I expression 
DNA methyltransferase Dnamt-1, Dnamt-3A and Dnamt-3B is a group of 
three enzymes, which take part in the methylation of DNA and are present 
in all mammalian cells. Dnamt-1 knock out (KO), Dnamt-3 (KO), Dnamt-all 
KO ES cell lines, in which all three enzymes are missing, were obtained 
from Prof. Hans R. Schöler (Max Planck Institute for Molecular 
Biomedicine, Münester). These cell lines were originally generated in Prof. 
Rudolf Jaenisch group, Whitehead Institute, MIT, USA. Wild type E14 and 
OG2 murine ES cell lines were also obtained from Prof. Schöler group ans 
served as controls. All Dnamt mutant ES cells were viable and contained a 
small percentage of methylated DNA and methyltransferase activity (Li et 
al. 1992). The OG2 and Dnamt-all KO ES cell lines express GFP under 
the Oct4 promoter, which is convenient for visualizing the pluripotent 
ESCs. 
Flow cytometric analysis of these cells cultured in the presence of LIF 
showed that H-2Kb molecules in Dnamt-1 KO (17.7%), Dnamt-3 (20.2%) 
and Dnamt-all KO (21.2%) ES cell lines were expressed at significantly 
higher fraction of cells compared to wild type E14 (1.1%) and OG2 (3.5%) 
ESCs. Dnamt-1, 3 and all KO cells stimulated with IFNγ exhibited only 
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slightly higher enhancement of H-2Kb expression compared to untreated 
KO cells (25.3%, 25.8% and 23.2%, respectively) (Figure 21). No induction 
of H-2Kb molecules was observed in E14 and OG2 ES cell lines, in which, 
respectively, only 2.8% and 3.5% of cells expressed H-2Kb molecules. 
These data indicate that Dnamt are only partially responsible for regulation 
of MHC class I expression and that they are not essential for their 
induction by IFNγ in ESCs cultured in the presence of LIF. Most likely, 
other mechanisms or chromatin modifying factors are responsible for 
maintaining MHC class I expression at low levels in undifferentiated ESCs. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Expression of MHC class I molecule in Dnamt knockout murine ES cell 
lines. Dnamt-1, Dnamt-3 and Dnamt-all knockout (KO) and wild type E14 and OG2 
murine ES cell lines were used to determine the expression of cell surface H-2Kb 
molecules in the presence or absence of IFNγ (100 ng/ml for 2 days). OG2 and Dnamt-all 
KO cells are transgenic lines that express EGFP under the control of Oct4 promoter. 
Analysis was performed by flow cytometry using H-2Kb-specific monoclonal antibody.by 
gating on viable cells. Data are given as means ± SEM of at least two independent 
biological experiments. 
 
 
III.2.3. Epigenetic modifiers 2,5-azacytidine and Trichostatin A 
increase the expression of MHC class I molecules in ESCs  
2,5-Azacytidine (2,5-aza) is a potent inhibitor of DNA methyltransferases 
leading to the reduction of DNA methylation. Demethylation activates 
genes by preventing gene silencing mechanisms. Trichostatin A (TSA) is 
used as an antifungal antibiotic and inhibits histone deacetylase (HDAC) 
family of enzymes. 2,5-aza and TSA act in a non-specific manner.  
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Figure 22. Synergistic effect of Trichostatin A and 2,5-Azacytidine on MHC class I 
induction in murine ES cells. CGR8 ESCs were treated with TSA (100 nM) and 2,5-aza 
(1 μM) individually and together for 2 days without or with IFNγ (100 ng/ml). Control cells 
were treated with DMSO because TSA and 2,5-aza were dissolved in DMSO. After 2 
days of treatment, cells were stained with the MHC class I antibodies and proper isotype 
controls (grey shaded histogramsand analyzed by flow cytometry by gating on viable 
cells. Data are representative of at least two independent biological experiments. 
 
 
To determine the effect of these agents on the expression of MHC class I 
molecules in ESCs, we treated the CGR8 ES cells with 2,5-aza (1 μM) and 
TSA (100 nM) separately or in combination for 2 days in presence or 
absence of 100 ng/ml IFNγ. Flow cytometric analysis demonstrated that 
the fraction of H-2Kb positive ESCs was slightly increased when cells were 
treated with TSA alone (12.5%, MFI=14.1) and 2,5 aza alone (16.0%; 
MFI=18.9) (Figure 22). In combination with IFNγ, TSA induced the H-2Kb 
expression on 42.8% of cells (MFI=21.9) and 2,5 Aza on 32.7% of cells 
(MFI=24.5). Control cells treated with DMSO did not express H-2Kb 
molecules above the background levels irrespective of IFNγ treatment. 
Interestingly, treatment of ESCs with both 2,5-aza and TSA resulted in 
even stronger induction of MHC class I molecules in the absence (58.82%, 
MFI=26.6) as well as in the presence of IFNγ (74.49%, MFI=45.1) (Figure 
22). These results suggest that epigenetic mechanisms involving both 
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DNA methylation and histone deacetylation participate in regulation of 
MHC class I molecules in ESCs.  
 
 
III.3. Biological consequences of STAT3 KD in ESCs  
 
Previous studies reported that ESCs were killed by NK cells and they were 
resistant to killing by cytotoxic T cells in vitro (Dressel et al. 2010; Drukker 
et al. 2002; Abdullah et al. 2007).  In our results, we showed that STAT3 
KD leads to the induction of MHC class I molecules in murine ESCs 
without changing their pluripotency.  Since MHC class I molecules play an 
important role in modulating killing by NK cells and CTLs, we checked the 
susceptibility of STAT3 KD murine ESCs towards NK cells and CTLs in 
syngeneic settings. 
 
III.3.1. Downregulation of STAT3 in murine ESCs reduces their lysis 
by syngeneic NK cells 
According to “missing self” hypothesis a very low or no expression of MHC 
class I molecules on target cells allows activation of NK cells by interaction 
with their activating ligands and leads to lysis of such target cells (Karre 
2008). We have earlier demonstrated that murine ES cells expressing very 
low levels of MHC class I molecules, were lysed by NK cells because they 
express the activating NKG2D ligands (Frenzel et al. 2009). Previous in 
vivo studies also demonstrated that low MHC class I expression and NK 
cells play vital role in controlling the survival of vascular progenitors 
derived from ES cells after syngeneic transplantation (Ma et al 2009). 
Therefore, it is expected that increasing the expression of MHC class I 
molecules on ES cells would reduce their killing by NK cells. Indeed, using 
a 51Cr-release cytotoxicity assay we found that upregulation of MHC class 
I molecules on ES cells after STAT3 KD significantly diminished (more 
than 50%) the lysis on αPIG ESCs (Figure 23A) and CGR8 ESCs (Figure 
23B) by poly(I:C) activated NK cells. YAC cells that were used as a 
positive control were lysed up to 80% at E:T ratio of 1:100 while C57sv 
fibroblasts serving as a negative control were not lysed by activated NK 
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cells. These data indicate that STAT3 maintains the expression of MHC 
class I molecules in native ES cells at sufficiently low levels to permit their 
efficient killing by NK cells. 
 
A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. STAT3 KD murine ES cells show reduced susceptibility to lysis by 
activated syngeneic NK cells in vitro. NK cell cytotoxicity assay was performed with 
STAT3 KD aPIG (A) and CGR8 (B) ES cells. In comparison to wild type and mock siRNA-
treated controls, both STAT3 KD murine ES cell lines showed approximately 50% 
reduced lysis. NK-sensitive YAC cell line was used as a positive control and murine 
C57sv fibroblasts served as a negative control in this assay. Data are given as means ± 
SEM of at least three independent biological measurements. 
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III.3.2. STAT3 partially inhibits the lysis of murine ESCs by CTLs 
The expression of H-2Kb molecules on ESCs at very low levels might be 
the reason for their relative protection from killing by CTL. To determine 
whether the upregulation of H-2Kb molecules by STAT3 KD in ES cells 
enhances their lysis by CTLs, ovalbumin (OVA)- expressing transgenic 
aPIG-CytOVA (clone A4) ESCs and C57sv-CytOVA fibroblasts were 
generated to serve as targets for cytotoxic syngeneic T cells in an in vitro 
cytotoxicity assay. OVA-specific effector T cells were generated by 
immunizing the OT1 transgenic mice with OVA protein and subsequent 
stimulation of splenocytes in vitro by synthetic ovalbumin-derived 
immunodominant SIINFEKL peptide. OT1 mice express on all T cells a T 
cell receptor, which recognizes the ovalbumin-derived T cell epitope 
SIINFEKL in a complex with H-2Kb MHC class I molecules.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. STAT3 KD in murine ES cells enhances their lysis by syngeneic 
cytotoxic CD8+ T lymphocytes in vitro. Ovalbumin (OVA)-specific cytotoxicity assay 
was performed as described in the Methods section. OVA–expressing ES cells (clone A4) 
and C57sv fibrobalsts were generated to stably express OVA in the cytosol. Wild type 
murine C57sv fibroblasts served as negative control. Data are given as means ± SEM of 
at least three independent biological measurements. 
 
 
Mouse C57sv fibroblasts that did not express OVA were not lysed by OT-1 
CTLs. In contrast, C57sv fibroblasts expressing OVA were strongly lysed 
(63.9% lysis at the E:T ratio of 100) (Figure 24). In contrast, control and 
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scrambled siRNA treated ES cells were not lysed by CTLs at any E:T ratio. 
However, after STAT3 KD the OVA-expressing ES cells were moderately 
lysed (17.9% lysis at the E:T ratio of 100), (Figure 24). These data indicate 
that STAT3 pathway plays an important role in regulating the susceptibility 
of ES cells to CTL-mediated lysis by downregulating the expression of 
MHC class I molecules.  
 
 III.4. Regulation of MHC class I expression in ES cell-
derived cardiomyocytes (ES-CMs) 
ES-CMs were used as a model for differentiated cells with the aim to 
determine to what extent the regulatory mechanisms of MHC class I in 
ESCs have changed in the course of differentiation and diversification of 
cell types. That is why, we decided to KD STAT3 gene in ES-CMs and 
checked the expression of MHC class I molecules in these differentiated 
cell-types. 
 
III.4.1. STAT3 KD in ES-CMs does not induce the expression of MHC 
class I molecules on their surface 
We have previously shown that, like undifferentiated ESCs, differentiated 
murine ES-CMs express flow cytometrically undetectable amounts of MHC 
class I molecules on their surface (Frenzel et al. 2009). To elucidate 
whether STAT3 plays a role in regulation of H-2Kb expression in ES-CMs, 
CMs were treated with STAT3 siRNA for 48 h and analyzed for the 
expression of MHC class I molecules at the transcript and protein level. 
Quantitative RT-PCR analysis confirmed that STAT3 mRNA expression in 
ES-CMs was strongly reduced by 85% in STAT3 siRNA treated cells as 
compared to control siRNA-treated cells (Figure 25A). In contrast, the 
expression of MHC class I heavy chain and STAT1 mRNA was not 
affected by any of these treatments (Figure 25A). Flow cytometric analysis 
revealed that H-2Kb molecules could not be detected on intact CMs and 
that no induction of these molecules could be elicited by treatment with 
STAT3 siRNA or scrambled siRNA647 (Figure 25B). These findings 
indicate that mechanisms responsible for the maintenance of low 
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expression levels of H-2Kb molecules diversified in the course of 
differentiation from undifferentiated ESCs to highly specialized cells, such 
as CMs. 
 
A. 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
Figure 25. The effect of STAT3 KD on expression of MHC class I molecules in 
murine ES cell-derived cardiomyocytes (CMs). A. RNA was isolated from STAT3 KD 
day 16 CMs and control cells cultured in the absence of IFNγ. Real-time PCR analysis 
was performed for STAT3, STAT1 and H-2Kb genes. The expression levels were shown 
relative to siRNA647-treated ESCs, which was set to value of 1. GAPDH gene was used 
as internal control. Data are given as mean ± s.e.m. of 6 replicates. These data are 
representative of two independent experiments. B. Flow cytometric analysis was 
performed using H-2Kb specific antibody with control, siRNA647 and STAT3 siRNA KD 
day16 CMs. This analysis was performed in two independent experiments. 
 
 
III.4.2. Effect of IFNγ on expression of components of MHC class I 
antigen processing machinery in ES-CMs 
We have previously shown that, unlike undifferentiated ESCs, ES-CMs are 
highly responsive to IFNγ and highly upregulate the MHC class I molecules 
after stimulation with this cytokine (Frenzel et al. 2009). Here we extend 
these data and show that in addition to transcripts for MHC class I α and β 
chains, IFNγ also stongly upregulates the expression of transcripts 
encoding various components of antigen processing machinery such as 
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LMP2, LMP7, TAP1 and TAP2 (Figure 26). As expected, these transcripts 
were not affected by IFNγ in undifferentiated αPIG ESCs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Comparison of expression of various MHC class I transcripts in 
undifferentiated ESCs, EBs and pure ES-CMs. RNA was isolated from C57sv 
fibroblasts, aPIG ESCs, day 16 EBs, and purified day 16 ES-CMs cultured in the 
presence or absence of IFN-γ (100 ng/ml) for 2 days. Real time PCR analysis of H-2Kb, 
β2M, LMP2, LMP7, TAP1 and TAP2 mRNA was performed using Syber green dye and 
GAPDH used as endogenous control.  
 
 
Interestingly, the induction of these transcripts by IFNγ was much stronger 
in ES-CMs than in C57sv fibroblasts and unpurified EBs at day 16 of 
differentiation. Surprisingly, under basal conditions transcripts for MHC 
class I molecules and selected antigen processing factors were expressed 
in ES-CMs at the same level like in undifferentiated ESCs (Figure 26). 
However, the expression of these molecules was highly inducible by IFNγ 
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in only in ES-CMs (MHC class I α chain by 126-fold, β2M by 404-fold, 
LMP2 by 115-fold, LMP7 by 80-fold, TAP1 by 82-fold and TAP2 by 40-
fold). In contrast, these transcripts were induced to a much lower extent in 
C57sv fibroblasts (MHC class I α chain by 1.6-fold , β2M by 2.29-fold, 
LMP2 by 6.1-fold, LMP7 by 2.06-fold, TAP1 by 3.04-fold and TAP2 by 
2.47-fold) and EBs (MHC class I α chain by 14.2-fold , β2M by 44.7-fold, 
LMP2 by 55.6-fold, LMP7 by 14.2-fold, TAP1 by 20.2-fold and TAP2 by 
9.2-fold). 
 
 
III.4.3. ES-CMs are partially lysed by CTLs only after induction of MHC 
class I molecules by IFNγ 
IN previous chapters we have shown that ESCs were not killed by specific 
CTLs under basal conditions. Moderate lysis could be achieved only when 
the concentrations of MHC class I molecules on their surface was 
increased by STAT3 KD. Under basal conditions, ES-CMs are also not 
killed by CTLs. We have shown above that IFNγ dramatically upregullates 
all components of the MHC class I antigen processing pathway in ES-
CMs, but not in ESCs. Therefore, we asked whether ES-CMs treated with 
IFNγ could be killed by CTLs more efficiently than ESCs.  
Using standard 51Cr-release cytotoxicity assay and ovalbumin system we 
show that positive control cells EG7OVA and C57sv-CytOVA were lysed 
by up to 40-50% by OVA specific CTLs while wild type C57sv fibroblasts, 
EL4 and αPIG ES-CMs, which did not express OVA, were not lysed by 
OVA specific OT1 CTLs, irrespective of IFNγ treatment (Figure 27A). 
Similarly, OVA expressing αPIG-CytOVA ES-CMs (clone A4) were also 
not lysed by OT1 CTLs at any E:T ratio. However, partial lysis was 
observed with αPIG-CytOVA ES-CMs (up to 20%) that were pretreated 
with IFNγ (Figure 27A).  
Interaction of active CTLs with their targets cells leads to secretion of IFNγ 
by cytotoxic CD8+ T cells. This phenomenon can be used to assess 
whether ES-CMs can be recognized by CTLs or not. For this, we 
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performed ELISA from samples that were collected in cytotoxicity assays 
shown above. As shown in figure 27B, OT1 CTLs did not secrete IFNγ 
when they were cocultured with C57sv fibroblasts, EL4 cells and aPIG ES-
CMs. Prestimulation of these cells by IFNγ did not affect this result. In 
contrast, OT1 CTLs secreted IFNγ in cocultures with control cells 
expressing OVA such as EG7OVA, C57sv-CytOVA and OVA-expressing 
ES-CMs. These results suggest that OVA-expressing ES-CMs were 
recognized by OVA-specific CTLs independently of the MHC class I levels 
on their cell surface but CTLs were able to partially kill only OVA-
expressing ES-CMs that expressed high levels of H-2Kb molecules after 
induction by IFNγ. Weak lysis of ES-CMs even after a dramatic induction 
of MHC class I molecules sugest that these cells possess specific 
mechanisms to protest them from killing by CTLs.  
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A.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. Interaction of ,urine ES-CMs and OVA-specific syngeneic cytotoxic CD8+ 
T lymphocytes (CTLs). A. CTLs were generated in syngeneic mice by injecting 
ovalbumin. Splenocytes were taken from ovalbumin immunized mice and restimulated 
with SIINFEKL in vitro. ES-CMs were treated with 100 ng/ml interferon gamma for two 
days prior to 51Cr-release assay. EG7OVA is an ovalbumin-expressing lymphoblastoid 
cell line, derived from parental EL4 cells. B. Samples were collected after 51Cr-release 
assay for ELISA assay. ELISA was performed to measure the IFNγ release using anti-
IFNγ antibody during CTLs interactions with different cell types in syngeneic settings.  
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IV. Discussion 
 
ESCs present a unique model to study early embryonic development and 
to study different genetic disorders. These cells also provide a platform to 
investigate developmentally programmed genes during embryonic 
progression. MHC class I genes, which are biologically relevant, are 
activated during embryonic development, whereas at birth most somatic 
cells display the antigens on their surface (Johnson 1993; Fiszer et al. 
1997). MHC class I genes play an unequivocally central role in the 
immune response (Li et al. 2010; Hansen et al. 2009), but have also been 
shown to influence reproductive behaviour and the development of the 
embryo (Warner et al. 1991; Tian et al. 1992; Hviid 2006). Therefore, it is 
essential to understand the immune privileged properties and the 
regulation of MHC class I molecules in ESCs. The aim of present study 
was to elucidate the mechanisms that regulate the expression of MHC 
class I molecules in murine ESCs at undifferentiated stage and after their 
differentiation to cardiomyocytes, which served as a model for a highly 
specialized cell type. Similar to an embryo capable of evading maternal 
immune system, ESCs possess unique immunological properties 
compared to typical transplantation grafts (Swijnenburg et al. 2005; Bonde 
et al. 2006; Magliocca et al. 2006; Abdullah et al. 2007; Saric et al. 2008). 
Consistent with previous findings, I showed that, in contrast to human 
ESCs, their murine counterparts express very low levels of MHC class I 
molecules and do not respond to IFNγ by upregulation of IFNγ responsive 
genes. My results indicate that MHC class I molecules in murine ESCs are 
regulated at different levels.  The dominant LIF/STAT3 pathway negatively 
regulates the MHC class I molecules in murine ESCs and iPSCs as 
demonstrated by STAT3 knock-down experiments which significantly 
increased the expression of these molecules at basal state as well as in 
response to IFNγ. As compared to fibroblasts, the expression of STAT1 
was very low in murine ESCs and IRF2 was either absent or present at 
negligible amount in these cells. STAT3 KD in murine ESCs demonstrated 
the dowregulation of epigenetic modifier genes Eed1, Dnamt1 and Jmjd1 
while Dnmt KO murine ESCs showed the partial upregulation of MHC 
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class I molecules on their surface. Moreover, the treatment of 2,5-aza and 
TSA to murine ESCs enhanced the MHC class I expression on their 
surface. Strikingly, STAT3 KD murine ESCs showed STAT1 
phosphorylation and more STAT1 transcriptonal activity as compared to 
control ESCs indicating the inhibitory role of STAT3 on IFNγ signaling. I 
have shown that relatively modest modulation of MHC class I molecule 
expression on the surface of ESCs affects their susceptibility towards NK 
cell and CTL cytotoxicity in vitro. Similar effect was also observed after 
more dramatic increase of MHC class I expression in ES-CMs that slightly 
increased their lysis by CTLs.  
 
Regulation of MHC class I in IFNγ treated state in ESCs 
 
The pathway of STAT1 activation is fundamental for IFNγ mediated pro-
apoptotic responses including expression and induction of MHC class I 
molecules in different cell types (Schroder et al. 2004). IFNγ is a significant 
cytokine that orchestrates many distinct cellular programs through 
transcriptional control over large number of genes including STAT1, MHC 
class I molecules and IFNγ-induced effects resulting in heightened immune 
surveillance and immune system function during infection. Several studies 
showed the impairment of STAT1/IFNγ pathway due to various 
mechanisms. One report demonstrated that the downregulation of IFNγ-R2 
chain impaired the responsiveness to IFNγ in T lymphocytes (Regis et al. 
2006). The authors showed that accumulation of IFNγ-R2 induces IFNγ-
induced apoptosis, whereas IFNγ-R2 chain internalization induces T cell 
unresponsiveness to IFNγ signaling. We showed that IFNγ receptors are 
expressed at the comparable levels on murine ESCs and EBs and were 
downregulated by IFNγ. However, despite the presence of its receptor, 
IFNγ did not seem to transduce the signal and induce its responsive genes 
in ESCs (Figure 9A,B).  
Previous reports demonstrated that the downregulation of IFNγ-inducible 
gene expression in human cancer cell lines is due to phosphatase 
mediated inhibition of JAK/STAT1 pathway (Choi et al. 2007; Rodriguez et 
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al. 2007). Choi and coworkers 2007 reported that IFNγ-induced expression 
of multiple genes is significantly reduced in human trophoblast-derived 
choriocarcinoma cells relative to Hela epithelial or fibroblasts cells due to 
the compromised tyrosine phosphorylation of JAK2 and STAT1. They 
successfully showed that treatment of choriocarcinoma cells with the 
tyrosine phosphatase inhibitor pervanadate significantly enhanced the 
IFNγ-inducible tyrosine phosphorylation of JAK and STAT1 and expression 
of IFNγ-inducible genes. Rodriguez et al elucidated that some melanoma 
cell lines did not induce MHC class I in response to IFNγ due to the 
absence of STAT1 phosphorylation. However, they did not find out the role 
of phosphatases in STAT1 phosphorylation. Many reports also described 
the unresponsiveness to IFNγ due to the absence of IFNγ regulatory factor 
1 and 2 (IRF1 and IRF2) or due to the defect in antigen processing 
machinery molecules (Harada et al. 1990; Nozawa et al. 1998; Dovhey et 
al. 2000; Rodriguez et al. 2007). Haradha H et al. described the absence 
of type I IFN system in murine embryonic carcinoma (EC) cells and 
showed that transcriptional activator (IRF1) and repressor (IRF2) were 
developmentally regulated in EC cells. They described that IRF1 and IRF2 
become functional only after cell differentiation. Rodriguez et al showed 
that ESTDAB-159 melanoma cells did not have IFNγ-mediated HLA class I 
expression due to epigenetic blocking of IRF1 transactivation, while 
Nozawa et al found functionally inactivating point mutation in tumor 
suppressor IRF1 gene in human gastric cancer. Dovhey et al reported that 
some cancer cell lines have abnormally low expression of TAP1 and LMP2 
and loss of their induction leads to the defect in IFNγ signaling pathway 
resulting in the inability of cancer cell lines to upregulate MHC class I 
antigen-processing pathway. In the present study, we have shown that 
IFNγ receptors are expressed on the surface of ESCs and that their 
absence can not be the reason for the unresponsiveness of ESCs towards 
IFNγ. However, as compared to C57sv fibroblasts, STAT1 protein levels as 
well as transcript levels were very low in ESCs and EBs (Figure 10A,B). It 
might be possible that each cell type requires minimum threshold 
expression of STAT1 for IFNγ response and low expression of STAT1 may 
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contribute to unresponsiveness of ESCs to IFNγ. Furthermore, 
phosphatases SHP1, SHP2, PTPB1 and molecules of the antigen 
processing machinery TAP1, TAP2, LMP2, LMP7, JAK1, JAK2 are also 
expressed at the transcript level on these cells (Figure 8B; Figure 11A), 
but were not induced by IFNγ. Interestingly, IRF1 was expressed but IRF2 
was not detectable at the transcript level in ESCs (Figure 11A). Therefore, 
it is possible that the inability of ESCs to respond to IFNγ may be based on 
several factors: low level of STAT1 expression, lack of IRF2 expression, 
and blockade of STAT1 activation by STAT3 signaling pathway. It is 
unlikely that the unresponsiveness to IFNγ is due to dysfunctional antigen 
processing and presentation pathway, because all analyzed components 
of this pathwas were expressed in ESCs, EBs and fibroblasts at similar 
levels. 
Another check point that may play a role in regulation of IFNγ signaling is 
the transport of phosphorylated STAT1 dimers into the nucleus that occurs 
through nuclear import proteins, known as importins. Yasuhara and 
coworkers demonstrated that mouse brain predominantly expresses 
importin-α5 (also known as Kpna1) while murine ESCs predominantly 
express importin-α1 (also known as Kpna2) but not importin-α5 (Yasuhara 
et al. 2007). This raises the possibility that importin-α undergoes subtype 
switching during neural differentiation. Indeed, they found that importin-α1 
switches to importin-α5 when ESCs differentiate into neural cells 
(Yasuhara et al. 2007). Another study conducted by McBride and 
colleagues reported that nuclear import of STAT1 was regulated by 
importin-α5 in HeLa cells (McBride et al. 2002). This group proposed that 
the importin-α5 shuttling receptor recognizes and binds to the nuclear 
localization signal (NLS) on the activated STAT1 dimer and effects 
translocation into the nucleus in association with importin-β (also known as 
Kpnb). In this study, we found that all importins were expressed at the 
transcript level in murine ESCs as well as in differentiating EBs (Figure 
11B), suggesting that STAT1 import may not be the reason for 
unresponsiveness to IFNγ in ESCs. This conculsion is indirectly supported 
by the finding that the responsiveness to IFNγ could be established in 
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ESCs by downregulation of STAT3 expression that led to enhanced 
STAT1 phosphorylation. However, we can not exclude the possibility that 
importin-α5 is absent at the protein level in ESCs and thus reduces the 
nuclear import of STAT1 and expression of STAT1 responsive genes, 
such as MHC class I molecules.  
LIF/STAT3 signaling maintains pluripotency of ES/iPS cells and is a 
dominant pathway, which might inhibit STAT1 pathway in these cells. A 
number of studies showed the contrasting role of STAT1 and STAT3 
signaling in different cell types (Hong et al. 2002; Qing et al. 2004). Hong 
and coworkers have shown that STAT1 plays a damaging role in Con A-
mediated hepatitis by activation of CD4+ T cells and NKT cells and directs 
hepatocytes towards death. On contrary, STAT3 protects against liver 
injury by suppression of IFNγ signaling and induction of antiapoptotic gene 
Bcl-XL. Furthermore, their results showed the SOCS3-mediated inhibitory 
cross-talk between STAT1 and STAT3 in hepatocytes in Con A-induced 
hepatitis. They demonstrated that STAT1-mediated induction of SOCS1 
gives negative feedback for STAT1 activation and attenuates activation of 
STAT3 in Con A-induced hepatitis, whereas, STAT3 play a more important 
role than STAT1 in inducing SOCS3 in the model of hepatitis. Taken 
together, these findings propose that T-cell-induced hepatiis is tightly 
controlled by mutual antagonism of IFNγ/STAT1 and IL6/STAT3 pathways, 
which regulate each other negatively through the induction of SOCS. 
Consistent with these results; our data showed that expression of SOCS3 
was reduced significantly in STAT3 KD murine ESCs while SOCS1 
remained unchanged (Figure 19B). This showed that SOCS3 but not 
SOCS1 was regulated by STAT3 in murine ESCs and may mediate 
inhibition of STAT1 phosphorylation. Interestingly, some groups reported 
that SOCS3 has been shown to negatively regulate STAT3 and STAT1 
activation by inhibition of JAKs (Naka et al. 1999; Nicola et al. 1999). 
Forrai and colleagues described that absence of SOCS3 reduces self-
renewal and promotes differentiation in murine ESCs (Forrai et al. 2006). 
Our results were also in line with previous studies indicating the opposing 
role of STAT3 activation on IFNγ/STAT1 signaling in hepatocytes. In 
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general, murine ESCs were differentiated into EBs in absence of LIF. 
Expectedly, LIF addition to ES-derived EBs drastically reduced the basal 
and IFNγ induced MHC class I expression, because LIF addition activates 
the STAT3 pathway. Most likely, the activation fo STAT3 pathway by 
readdition of LIF to EBs negatively affected the basal expression of MHC 
class I molecules in the absence of IFNγ as well as the STAT1 
phosphorylation and transcriptional activity in the presence of IFNγ leading 
to the reduced expression of MHC class I molecules.  
 
Regulation of MHC class I in basal state in ESCs 
 
Of interest, the dominant LIF/STAT3 pathway in ES/iPS cells might be 
possible reason for the low expression of MHC class I molecules at basal 
state in the absence of IFNγ. The MHC class I molecules were upregulated 
in ES/iPS cells also when STAT3 transcripts were knocked down in the 
absence of this cytokine. Since MHC class I expression was induced by 
STAT3 KD even without IFNγ, other mechanisms unrelated to STAT1 
signaling pathway must be responsible for this phenomenon. Epigenetic 
modifier genes Dnamt1, Eed1 and Jmjd1 were downregulated in STAT3 
KD ESCs, with Eed1, a crucial gene for Dnamt enzyme recruitment, being 
the most significantly downregulated and therefore may act as a potentially 
responsible mediator of STAT3-suppressive action on MHC class I 
expression (Figure 20). Interestingly, Dnamt KO murine ESCs showed 
enhanced MHC class I expression on a small fraction of cells, which was 
slightly inducible by IFNγ (Figure 21). Therefore, Dnamt enzymes do not 
seem to play a crucial role of regulation of MHC class I expression in 
ESCs. However, the involvement of epigenetic mechanisms in regulation 
of MHC expression in ESCs was reported recently by showing 
hypermethylation for MHC class II genes and demethylation for MHC class 
I genes in human ESCs/iPSCs (Suarez-Alvarez et al. 2010). They showed 
that treatment of murine ESCs with 2,5-aza and trichostatin A not only 
increased the expression of classical class I and class II and non-classical 
MHC molecules but also genes related to antigen processing machinery 
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such as TAP-2, TPN, and LMP-7. In this report, they also demonstrated 
that combined effect of epigenetic modifiers enhanced the expression of 
MHC class I molecules and β2M. Consistent with this, I also showed that 
expression of MHC class I molecules increased in murine ESCs by 
treatment with 2,5-aza and trichostatin A. Combined effect synergistically 
increased the expression of MHC class I molecules which were further 
inducible by IFNγ (Figure 22). Therefore, STAT3 pathway in ESCs most 
likely keeps the expression of MHC class I molecules by modulating the 
expression and activity of specific epigenetic factors, such as Eed1 (Ura et 
al. 2008). 
STAT3 KD ES cells maintained their pluripotency and showed similar 
teratoma growth kinetics in RAG2-/-γc-/- immunodeficient mice (Figure 14D). 
Expression of Oct4, Nanog, Sox2 and Tbx3 did not change in STAT3 KD 
ESCs while expression of Klf4 was reduced significantly, which is in 
accordance with Klf4 being the immediate downstream target to STAT3 
(Figure 14B). These findings were in the line with evidence of other 
reports. Niwa and coworkers demonstrated that LIF signals enter into the 
cells through STAT3 and PI(3)K pathway and maintain the pluripotency of 
ESCs (Niwa et al. 2009). They have shown that the LIF signal is integrated 
into the core regulatory circuitry of pluripotency of murine ES cells via 
these two parallel pathways: The JAK-STAT3 activates Klf4 and then Sox2 
but not Nanog, and the PI(3)K-Akt pathway activates Tbx3 and then 
preferentially Nanog (Figure 28). Since some studies demonstrated that 
PI(3)K pathway also plays an important role in maintaining the 
pluripotency of murine ESCs (Chen et al. 2010; Storm et al. 2009), the 
possible reason for the undisturbed pluripotency of STAT3 KD ES cells 
could be the retention of a fully active PI(3)K pathway by LIF. Previous 
reports have demonstrated that constitutive expression of STAT3 is 
sufficient to stop differentiation of murine ES cells even in the absence of 
LIF (Matsuda et al. 1999), whereas dominant negative form of mutant 
STAT3 could abolish the pluripotency of mouse ES cells even if 
maintained in the presence of LIF (Niwa et al. 1998; Raz et al. 1999). This 
indicates that STAT3 is essential for maintaining the pluripotency of ESCs.  
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Another possible reason for the inability of transient STAT3 KD to affect 
the pluripotency of murine ES cells in the presence of LIF is the partial 
retention of STAT3 mRNA expression in ESCs (at about 20% of normal 
levels).  
Furthermore, Xie and coworkers reported that murine ESCs retain active 
STAT3 for up to 4 to 6 days upon removal of LIF (Xie et al. 2009). The 
imaging of STAT3 signaling pathway during mouse ES cell differentiation 
revealed that STAT3 activation is required in both undifferentiated and 
differentiated stages because of STAT3’s ability to generate a diversity of 
biological outcomes in different cell types (Katoh et al. 2007). The 
prolonged retention of active STAT3 upon LIF removal in ESCs may 
explain the failure to induce MHC class I molecules in undifferentiated 
ESCs under this experimental condition in this study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Diagram of the parallel circuitry of the LIF signal pathway integrating 
into the transcription factor network. The JAK-STAT3 pathway activates Klf4, whereas 
the PI(3)K-Akt pathway stimulates the transcription of Tbx3. The MAPK pathway 
antagonizes the nuclear localization of Tbx3. Klf4 and Tbx3 mainly activates Sox2 and 
nanog, respectively, and maintain expression of Oct3/4. Transcription of all these 
transcription factors is positively regulated by Oct3/4, Sox2 and Nanog, which may confer 
robustness and stable expression in the absence of all signals. (Niwa, H,  Nature, 2009) 
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Differential regulation of MHC class I in ESCs and ES-CMs 
 
The role of MHC class I in the initiation and extent of NK cell-dependent 
killing has been extensively investigated and debated as the concept of 
‘missing self ‘hypothesis (Lanier 2005; Yokoyama et al. 2008). Most of the 
studies reported that undifferentiated ESCs, having a very low level of 
MHC class I, were recognized and lysed by natural killer (NK) cells in vitro 
(Dressel et al. 2010; Drukker et al. 2002; Frenzel et al. 2009). Ma and 
coworkers described that MHC class I expression on ES cell-derived 
vascular progenitor cells is critical for syngeneic transplant survival (Ma et 
al. 2010). Their study clearly pointed out that IFNγ-induced expression of 
MHC class I by ESC-derived progenitor cells was linked with attenuated 
host NK cell attack, enhanced graft survival, and the further differentiation 
of transplanted ESC-derived cells into vascular smooth muscle cells and 
endothelial cells. Our group revealed the role of natural-killer group 2 
member D (NKG2D) ligands and intracellular adhesion molecule 1 
(ICAM1) in NK cell-mediated lysis of murine ES cells and ES-CMs (Frenzel 
et al. 2009). They showed that NKG2D and ICAM1 play key role in lysis of 
ESCs by activated NK cells, on contrary ES-CMs are not lysed by 
activated NK cells due to the lack of detectable amount of NKG2D and 
ICAM1 on their surfaces. This differential sensitivity of ES cells and ES-
CM to NK cells could be useful for selective elimination of residual ESCs in 
grafts of differentiated cells to prevent teratoma formation. In the present 
study, we have shown that STAT3 KD murine ESCs have an enhanced 
expression of MHC class I molecules resulting in the reduced lysis by 
activated syngeneic NK cells. Our results suggest, at least in a syngeneic 
setting, that the induction of MHC class I after transient KD of STAT3 gene 
during in vitro differentiation of ESCs may improve the subsequent survival 
and immune integration of ESCs- derived differentiated derivatives after 
transplantation. 
Previous reports demonstrated that murine ESCs lack MHC class I 
expression at any passage number (David-Watine et al. 1987; Tian et al. 
1997). Our group showed that MHC class I molecules are expressed at 
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transcript level in undifferentiated murine ESCs and its derived EBs, 
however the protein level expression of these molecules were below the 
level of detection by flow cytometry in murine ESCs (Abdullah et al. 2007). 
They reported that murine ESCs and EBs express cytoprotective 
molecules cathepsin B and serine protease inhibitor-6 (SPI-6) and 
revealed that SPI-6 expression protects murine ESCs from lysis by 
antigen-specific CTLs. Consistent with these reports, I have confirmed the 
low level expression of MHC class I molecules and presence of other 
immunomodulatory molecules in ESCs and its derived EBs (unpublished 
data). Moreover, the data presented in this thesis showed that the 
increased expression of MHC class I molecules allows for the partial lysis 
of murine ESCs by antigen-specific CTLs after STAT3 KD (Figure 24).  
In this study, it was very interesting to note that unlike ESCs, MHC class I 
molecules and their genes were up regulated in ES-CMs to a much higher 
extent than in fibroblasts or EBs by IFNγ treatment (Figure 26). However, 
basal level expression of MHC class I molecules was same in ES-CMs 
and undifferentiated ESCs. Unlike in ESCs, downregulation of STAT3 did 
not induce MHC class I molecules in ES-CMs. Drug selected murine ES-
CMs were resistant to lysis by antigen-specific syngeneic cytotoxic CD8+ T 
cells in vitro, despite their recognition by T cells as shown by IFNγ release 
in an ELISA assay (Figure 27). However, upregulation of MHC class I 
molecules on ES-CMs by IFNγ led to their partial lysis by CTLs. Taken 
together, our findings demonstrated that in both cases either STAT3 KD in 
murine ESCs or IFNγ treatment in ES-CMs lead to the induction of MHC 
class I molecules on their surface and partial lysis by antigenic-specific 
CTLs. 
 
 
Cancer evades immune system by down regulating the MHC class I 
expression on the surface of cells and most of the studies showed the 
apoptotic role of STAT1 and pro-apoptotic role of STAT3 gene in different 
tumor cell lines (Choi et al. 2007; Rodriguez et al. 2007; Regis et al. 2008). 
Immunotherapy is an important approach to cancer treatment, therefore, it 
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is essential to understand the mechanisms by which these tumors 
circumvent IFNγ signaling, thereby representing the potential mechanism 
of cancer cytokine-resistance to therapy. Indeed, suppression of STAT3 
gene and activation of STAT1 gene can be also useful for killing the 
cancer cells by CTLs and dissecting the STAT1 pathway and opposing 
role of STAT1-STAT3 in ESCs can give insight into cancer biology.  
Further effort should be made to determine the interaction partners 
between these two essential transcriptional factors (STAT1 and STAT3) of 
biological system that would further help to design stratiges for drug 
development against tumor cells. Nevertheless; this present study could 
be helpful in designing the strategies to prevent teratoma by ESCs which 
is a great hurdle in cell transplantation study. Understanding the complex 
regulatory mechanisms that govern pluripotency, differentiation and 
immune interactions of ESCs and its derivatives will undoubtedly be an 
obligatory hurdle that will need to be overcome for the successful 
implementation of cell-based regenerative therapies. 
Previous studies demonstrated the crucial role of MHC class I molecules 
in reproduction and development of embryos (Warner et al. 1991; Tian et 
al. 1992; Boyson et al. 1997; Christiansen et al. 1997; Tarin 1997; 
Fernandez et al. 1999). Warner and Tian and co-workers demonstrated 
that Qa-2, a nonclassical MHC antigen, has been shown to influence 
dramatically the timing and rate of preimplantation cleavage division, 
clearly indicating a developmental role both before and after implantation. 
Intriguingly, MHC genes, in particular, appear to play a similar role in 
determining and influencing longevity, since mice with faster cleavage 
rates have shorter life spans than their slower congenic counterparts 
(Tarin 1997). However, in humans the situation is considerably harder to 
study. Because, not only is the arrangement of the MHC genes quite 
different from that in the mouse (Trowsdale 1995), but also the 
physiological and anatomical characteristics of pregnancy are not the 
same. MHC class 1b genes and their products (HLA-E,-F,-G) have been 
identified in human embryos, and many investigators believe that they play 
a role in reproductive success (Johnson 1993; Fiszer et al. 1997). 
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However, HLA protein expression and function does not appear essential 
for fetal survival, since an individual with a rare deletion resulting in failure 
of HLA-G protein expression has been reported. This present study is the 
first study which uses murine ESCs and their differentiated derivatives as 
a model to dissect the regulation of MHC class I molecules and 
demonstrates that STAT3 negatively regulates the expression of these 
molecules. I believe that ESCs represent an excellent model framework 
within which to study immunological tolerance and allorecognition, as 
mechanisms involved in the prevention of the rejection of these cells are 
likely to overlap with those involved in tolerance induction per se. 
 
Proposed model of regulation of MHC class I molecules in 
murine ES cells 
In the present study, I have explored the role of STAT3 signaling pathway 
in the regulation of MHC class I molecules on murine ESCs at basal state 
and in the presence of immunomodulatory cytokine IFNγ. The LIF/STAT3 
pathway keeps the expression of MHC class I molecules low under native 
conditions. The STAT3 signaling also prevents the stimulatory effect of 
IFNγ on MHC class I molecule expression by inhibiting the phosphorylation 
of STAT1 and its transcriptional activity in ESCs (Figure 29).  
However, IFNγ is also unable to strongly induce the MHC class I 
expression in ESCs because they contain very low levels of STAT1 protein 
as compared to good IFNγ-responder cells, such as fibroblasts. 
Interestingly, IRF-2 is absent in murine ESCs and could be another reason 
for low expression of MHC class I molecules and their unresponsiveness 
to IFNγ (Figure 29). 
STAT3 also appears to mediated downregulation of MHC class I 
molecules at the epigenetic level. STAT3 regulates the expression of 
several epigenetic modifiers, especially the Eed1 and possible the JmjD1 
and Dnamt1, that could affect the methylation of promoter regions 
controlling the expression of MHC class I heavy and light chain transcripts 
in ESCs. Indirect evidence for this assumption is provided by the 
observation that the expression of MHC class I molecules on Dnmt1 KO 
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and TSA/2,5-aza-treated ESCs is higher than in wild type or untreated 
cells, respectively (Figure 29). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29.  Schematic representation of model of regulation of MHC class I 
molecules in murine ES cells. In normal cell type, IFNγ binds to IFNγ receptors and LIF 
binds to gp130 receptors to activate STAT1 and STAT3 pathways, respectively. However, 
STAT3 KD experiments demonstrated that STAT1 transcriptional activity and its 
phosphorylation were negatively regulated by STAT3 signaling-a dominant pathway in 
murine ES cells. Epigenetic mechanisms also seem to negatively regulate the expression 
of MHC class I molecules in murine ESCs. 
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V.1. Materials and Methods 
 
V.1.1.    Cell Lines 
 
 
Cell line Description 
HES2 
Human ES cell line (WiCell Research 
Institute (Madison, WI, USA) 
 
αPIG44-ES/aPIG44-ES 
 
Transgenic murine embryonic stem cell 
line, expressing the puromycin N-acetyl 
transferase and IRES-linked green 
fluorescent protein (GFP) under control 
of the cardiac α-MHC promoter (made 
by Eugen Kolossov) 
A4 ova 
aPIG44 trangenic ES cell line 
expressing ova (generated by Charis 
Satrazami in AG Saric) 
  
CGR8-ES 
Murine ES cell line (provided by Prof. 
Sachinidis lab, Institute for 
Neurophysiology) 
 
AT25 
 
Transgenic murine iPS cell line 
(provided by Rudolf Jänisch lab, USA), 
expressing the green fluorescent 
protein (GFP) under control of the 
cardiac α-MHC promoter (generated by 
Azra Fatima in AG Saric) 
 
EG7ova 
 
OVA-expressing EL4 cells, mouse 
strain C57BL/6N (ATCC) 
 
EL4 
 
Mouse lymphoma cell line, mouse 
strain C57BL/6N (ATCC) 
 
Dermal fibroblasts (C57sv) 
 
Mouse strain C57BL/6 (Millipore) 
CF-1 MEFs Mouse embryonic fibroblasts (MEFs) 
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isolated from CF-1 mouse strain 
MEF-NeoR Neomycin resistant MEFs 
Dnamt-1, Dnamt-3 and Dnamt-all KO DNA methyl transferase enzyme 
(Dnamt) 1, 3 and all knockout murine 
ES cell lines (generated by Rudolf 
Jänisch lab at MIT, USA, and provided 
by Hans Schöler, Max Planck Institute, 
Münster) 
OG-2 Murine ES cell line expressing GFP 
under Oct4 promoter (provided by Hans 
Schöler, Max Planck Institute, Münster) 
 
 
V.1.2.    Mouse Strains 
 
C57BL/6, 129sv, and OT-1 mice were originally obtained from Charles 
River Laboratories (Sulzfeld, Germany). Rag2-/-γc-/- mice were obtained 
from Mamoru Ito (Central Institute for Experimental Animals, Tokyo, 
Japan) and were bred and maintained in a pathogen-free animal facility. 
OT-1 mouse is on a C57BL/6 background (H-2Kb) and expresses a 
transgenic T-cell receptor specific for the SIINFEKL peptide of ovalbumin 
(OVA) in a complex with H-2Kb MHC class I molecules. Rag2-/-γc-/- mice 
are immunodeficient mice lacking B cells, T cells and NK cells in their 
immune system. Animal experiments were approved by the Ethics 
committee of the Government of Cologne and performed in accordance to 
the German animal protection law. 
 
V.1.3.    Molecular Biology reagents 
 
Reagent Catalogue No. Supplier 
TRIzol reagent  15596026 Invitrogen 
DNAeasy Blood and Tissue kit 69504 Qiagen 
Plasmid Maxi kit K210017 Invitrogen 
JumpStart  REDTaq ReadyMix P0982 Sigma 
dNTP Mix 18427013 Invitrogen 
DNase I 18068015 Invitrogen 
5x or 10x first strand buffer 810462 Invitrogen 
Random Primers  48190011 Sigma 
SuperScript II RNase H- Reverse 
Transcriptase 
18064014 Invitrogen 
Lipofectamine 2000 11668019 Invitrogen 
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V.1.4.    Cell culture reagents 
 
Medium Composition Intended use 
20% DMEM 
F12+Glutamax (1X) 
DMEM F12 + Glutamax (GIBCO), 
20% KOSR, 1X NEA, 50 μM ß-
Mercaptoethanol, 1X Pen-Strep and 
bFGF (4 ng/ml for human ES and 50 
ng/ml for human iPS cells) 
Human ES cell 
culture 
KO DMEM KO DMEM + conc? Glutamine 
(GIBCO), 1X NEA, 50 μM ß-
Mercaptoethanol, 1X Pen-Strep 
Cardiac 
differentiation 
15% DMEM DMEM + Glucose + conc? Glutamine 
(GIBCO), 15% FBS, 1X NEA, 50 μM 
ß-Mercaptoethanol, LIF 1000 U/ml 
(Invitrogen) 
Murine αPIG ES 
cell culture 
10% GMEM 
 
GMEM + conc? Glutamine (GIBCO), 
10% FBS, 1X NEA, 50 μM ß-
Mercaptoethanol 
Murine CGR8 
ES cell culture 
5% DMEM DMEM + Glucose + conc? Glutamine 
+ 5% FBS 
Fibroblats 
culture 
10% RPMI 
 
RPMI, 10% FBS, 50 μM ß-
Mercaptoethanol, L-Glutamin 1 mM, 
Sodium pyruvate 110 µg/ml, 1X NEA, 
IL-2 100 U/ml , SIINFEKL 10-9M 
In vitro 
stimulation of 
CTLs 
Freezing medium 80% DMSO (GIBCO), 20% FBS Cryopreservation 
of cells 
Basic fibroblasts 
growth factor (bFGF) 
Peprotech Human ES 
culture 
Leukemia Inhibitory 
factor (LIF)  
Millipore Murine ES 
culture 
Trypan blue stain 
(0.4%) 
GIBCO Cell counting 
Trypsin-EDTA 
(0.05%) 
Sigma Cell-passaging 
Knockout Serum 
Replacer (KOSR) 
Gibco Cell culture 
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Fetal bovine serum 
(FBS) 
Gibco Cell culture 
 
 
V.1.5.    Radioactive material 
 
For cytotoxicity experiments, Na251CrO4 were obtained from Hartmann- 
analytic GmbH, Germany (Activity: 74 Mbq (2 mCi), Size 400 μl, Code: 
Cr-RA-8, Catalogue No. 150496). 
 
V.1.6.    Common reagents 
 
Reagent Catalogue No. Supplier 
Agarose  16500500 Invitrogen 
Albumin-Fraktion V pH 7,0 
(BSA) 
A1391,0250 AppliChem 
CD8a (Ly-2) MicroBeads 
mouse  
130-042-401 Miltenyi Biotec 
Anti-NK (DX5) MicroBeads 
mouse 
130-052-501 Miltenyi Biotec 
16% paraformaldehyde 18814-20 Polysciences 
Agar Agar  9002-18-0 Roth 
DPBS  14190169 GIBCO 
DTT 844789 Roth 
Ethanol A1613,1000 AppliChem 
Ethidium bromide 15585011 Merck 
Gelatin powder G1890-100G Sigma 
Glycerol (99%) G5150-1L Sigma 
Interferon-γ (IFNγ) PMC4034 Invitrogen 
Interleukin 2 (IL-2) PHC0026 Invitrogen 
Isopropanol  A0900,1000PE AppliChem 
MACS-Buffer 130-091-221 Miltenyi Biotec 
Ovalbumin (albumin from 
chicken egg white) 
A5503-5G Sigma 
SIINFEKL (OVA257-264) S7951 ProImmune 
Sodium chloride  7647-14-5 Roth 
Tris base 5429.3 MERCK 
Trypton  07-119 Roth 
Yeast extract  07-079 Roth 
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CellWash 554723 BD Pharmingen 
Geneticin 10131019 Invitrogen 
Puromycin P15-019 PAA 
Ampicillin 1503,5 Biomol 
Ethanol/Methanol absolute 500156 Applichem 
 
 
V.1.7.    Primers 
 
Gene  NCBI 
Accession 
Sequence (5’ to 3’) Size 
(nt) 
Ta, 
°C 
mH2Kb 
 
 
NM_001001892
.2 
F-GCGGCTCTCACACTATTCAGGT 
R-TTCCCGTTCTTCAGGTATCTGC 259 60 
mβ2M 
 NM_009735.3 
F-GTCTTTCTGGTGCTTGTCTC 
R-GGCGTATGTATCAGTCTCAG 276 60 
mSTAT1 NM_009283 F-CCTCTTCCAGCAGCTCATTC R-TGTGTGCGTACCCAAGATGT 241 60 
mSTAT3 NM_0011486 F-TCACTTGGGTGGAAAAGGAC R-TGGTCGCATCCATGATCTTA 129 60 
mSOCS1 NM_009896 F-CTTAACCCGGTACTCCGTGA R-GAGGTCTCCAGCCAGAAGTG 210 60 
mSOCS3 NM_007707 F-CCTTTGACAAGCGGACTCTC R-GCCAGCATAAAAACCCTTCA 216 60 
mJAK1 NM_146145.2 F-CATCCCAGTCTCTGTGCTGA R-GCTCCTTGCAAGATGGAGTC 236 60 
mJAK2 NM_008413.2 F-TCCTTGACGGAGAGCAAGTT R- GAAGGGAAAGGTCCCTGAAG 292 60 
mPTP1B NM_011201.3 F-GACTCGTCAGTGCAGGATCA R- GCCTGAGCACTTTGAAGACC 299 60 
 
mSHP1 
 
NM_001077705
.1 
 
F- AACCAGCTGCTAGGTCCAGA 
R-CTGCTGTGTCATGCTCCCTA 
241 60 
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mSHP2 NM_011202.2 F-TTCTCACCAGCACACAGAGG R-CTCGCTGTCTCAAATCCACA 300 60 
mKpna1 NM_008465 F-CCTGAGGCTTGGAGAACAAG R-GCTGCTGGCTAAGATCAACC 218 60 
mKpna2 NM_010655 F-GGAGCACTTGCAGTCTTTCC R-CCACCGCTGGTATAGTTGGT 221 60 
mKpna6 NM_008468 F-CTAAATGGTGCGACCCAACT R-CCAGCTATGGCAGAAGGAAG 244 60 
mKpnab1 NM_008379 F-CTGTCCACCTGCTGTGAAGA R-GGTGCCAGGTAGACATCGTT 290 60 
mTAP1 NM_013683 F-CCGCTGCTATTTGGAAGAAG R-TGTCATAGCCCTGAGGGAAC 139 60 
mTAP2 NM_011530 F-AAGGTGGTGGGGCTCTACTT R-GGGGGTTGTACACCTTCTCA 109 60 
 
mLMP2 
 
NM_013585.2 
 
F-CATCATGGCAGTGGAGTTTG 
R-ACCTGAGAGGGCACAGAAGA 
 
136 60 
mLMP7 NM_010724.2 F-CAGTCCTGAAGAGGCCTACG R-CACTTTCACCCAACCGTCTT 121 60 
mIRF1 NM_008390 F-AGGGCTTAGGAGGCAGAGTC R- TCTAGGGCCAGTGCTATGCT 219 60 
mIRF2 NM_008391 F-CTTATCCGAACGACCTTCCA R- ATGTCTGGCGGGTTAGTGAC 258 60 
   
mDnmt1 
    
NM_010066.3 
       
 F-TGAGGAAGGCTACCTGGCTA 
 R-GTCTGCCATTTCTGCTCTCC 
 
142 60 
mEed1 NM_021876.2 F-CAACTGTGGGAAGCAACAGA R-ATAGAGGGTGGCTGGTGTTG 147 60 
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mJmjd1a NM_0173001.1 F-ACCATGGTCCAGCAAAGTTC R-TTCCCACTGGTAAGGTCAGC 143 60 
mIFNγ-
R1 NM_010511.2 
     
F:ATTCCTGCACCAACATTTCTG 
R:ACGGAGAGCTGTTCTTCCTT
C 
 
208 60 
mOCT3/4 NM_013633 F: AGCCGACAACAATGAGAACC R: TGATTGGCGATGTGAGTGAT 168 61 
mSOX2 NM_011443 F: TACCTCTTCCTCCCACTCCA  R: TCTCCAGTTCGCAGTCCAG 212 61 
 
mNanog 
 
NM_028016.2 
 
F:AGGGTCTGCTACTGAGATGTCCTG 
R:CAACCACTGGTTTTTCTGCCACCG 
 
 
364 
 
 68 
mTbx3 NM_011535.2 
 
F: AGATCCGGTTATCCCTGGGAC 
R: CAGCAGCCCCCACTAACTG 
 
200 60 
 
mKlf4 
 
NM_010637.2 
 
F-CCAAAGAGGGGAAGAAGGTC 
R-CTGTGTGAGTTCGCAGGTGT 
 
 
 124 
 
 60 
 
mINDO 
 
NM_008324.1 
 
F:GTACATCACCATGGCGTATG 
R:CGAGGAAGAAGCCCTTGTC 
 
 
245 60 
 
mCTSB 
 
NM_007798.2 
 
F:GGCTTTGACTGCAGGACTTC 
R:GGCTTTGACTGCAGGACTTC 
 
 
205 
 
60 
 
mTGF-β 
 
NM_011577.1 
 
F:TGAGTGGCTGTCTTTTGACG 
R:TCTCTGTGGAGCTGAAGCAA 
 
 
293 
 
60 
 
hINDO 
 
NM_002164.5 
 
F:GCGCTGTTGGAAATAGCTTC 
R:CAGGACGTCAAAGCACTGAA 
 
234 
 
60 
 
hCTSB 
 
NM_001908.3 
 
F:CACTGACTGGGGTGACAATG 
R:AACCACAGGCTGGGATGTAG 
 
 
293 
 
60 
 
hTGF-β NM_000660.3 
 
F:GGGACTATCCACCTGCAAGA 
R:CCTCCTTGGCGTAGTAGTCG 
 
239 
 
60 
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V.1.8. Antibodies used for immunoblotting 
 
Antibody 
specificity 
Catalogue #, 
clone 
Provider Working dilution 
STAT1 sc-346, E-23 Santa Cruz 1:500 
pSTAT1 (Y701) sc-8394, A-2 Santa Cruz 1:1000 
STAT3 sc-483, K-15 Santa Cruz 1:1000 
Alkaline 
phosphatase 
conjugated anti-
rabbit IgG 
A-3687 Sigma 1:10,000 
Alkaline 
phosphates 
conjugated anti-
mouse IgG 
A-3562 Sigma 1:10,000 
 
 
V.1.9. Antibodies used for flow cytometry 
 
Antibody 
specificity 
Catalogue #, 
clone 
Provider Working dilution 
IgG-PE P8547 Sigma 1:100 
pSTAT1 (Y701)-
alexa488 
612596  BD Pharmingen 1:10 
IgG2a-alexa488 558055, MOPC-
173 
BD Pharmingen 1:10 
H-2Kb-PE 553570, AF6-88.5 BD Pharmingen 1:100 
IgG2a-PE Sc-2867 Santa cruz 1:100 
SSEA-1 sc-21702, 480 Santa Cruz 1:100 
IgM sc-3881 Santa cruz 1:100 
IFNgR-α chain-
biotin 
558771, GR20 BD Pharmingen 1:100 
Rat-IgG2a sc-3883 Santa cruz 1:100 
IFNgR-β chain-
biotin 
559917 BD Pharmingen 1:100 
Hamaster-IgG-
biotin 
554010 BD Pharmingen 1:100 
Tra-1-81-FITC sc-21706 Santa Cruz 1:100 
IgM-FITC F9259 Sigma 1:100 
 92
 
V.1.10. siRNA sequence 
 
STAT3 siRNA ID: s74452 (Ambion) 
Sense strand (5’-3’): GAGUUGAAUUAUCAGCUUAtt 
Antisense strand (5’-3’): UAAGCUGAUAAUUCAACUCag 
 
Scrambled siRNA AlexaFluor 647  
All star negative control siRNA-647 (QIAGEN) 
 
 
 
V.1.11.    Glassware and plastics 
 
Description Supplier 
Tissue culture 6-,12-, 24- ,48- and 96-well plates TPP 
Tissue culture dishes Falcon, BD 
Tissue culture flasks (Cellstar) Greiner 
Cell-strainer (40uM) Falcon, BD 
CryoTube 1.8ml vials NUNC 
Disposable scalpel FEATHER 
Electroporation cuvette (0.4 cm, gap 50) Bio-RAD  
Pipette tips SARSTEDT, Labomedic 
PP-test tubes  (Cellstar) Greiner 
Safe lock tubes Eppendorf 
Serological pipettes  (Cellstar) Greiner 
LS Columns plus tubes (general items) Miltenyi Biotec 
Neubauer improved counting chamber Laboroptik 
 
 
V.1.12. Instruments and devices 
 
Description Supplier 
FACScan (with CellQuest® software) Becton Dickinson  
Gamma counter PerkinElmer   
MACS MultiStand Miltenyi Biotec 
Centrifuge 5417R Eppendorf 
Centrifuge Varifuge RF  Heraeus Sepatech 
BioVortex V1 G Kisker 
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Cell Chamber Neubauer Improved Neubauer 
Gel Electrophoresis Power Pac 300 Bio-RAD 
Gel Imager and UV-System Intas 
Gene Pulser Electroporation System BIO-RAD 
Pipettes GILSON, Eppendorf 
Thermocycler Mastercycler personal Eppendorf 
Thermomixer Comfort Eppendorf 
Sterile Bench Thermo Scientific 
Nitrogen Tank Cryotherm CHRONOS 
Microscope Axiovert 10 ZEISS 
Microscope TELAVAL 31 ZEISS 
Microwave oven Easytronic Whirlpool 
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V.2. Methods 
 
V.2.1. Culture of undifferentiated ESCs/iPSCs and other cell lines 
 
Human ES cell line HES-2 was generated by the ES Cell International 
(Singapore, http://www.escellinternational.com/about_esi/index.html) and 
obtained from the repository at the WiCell Research Institute (Madison, 
WI, USA, http://www.wicell.org/). The ES cells were maintained on 
irradiated MEFs in DMEM/F12 medium supplemented with Glutamax, 20% 
knockout serum replacer, 1% nonessential amino acids, 0.1 mM β-
mercaptoethanol (Invitrogen, Carlsbad, CA, http://www.invitrogen.com) 
and with 4 ng bFGF (Peprotech, Rocky Hill, NJ, USA, 
www.peprotech.com). Culture media were changed daily and cells were 
passaged by manual dissection of cell clusters every five to six days.  
D3 ES cell-derived transgenic clone αPIG44, E14, OG2, and Dnmt KO ES 
cell lines were maintained on irradiated MEFs in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 15% fetal bovine serum 
(FBS), 1X nonessential amino acids, 2 mM L-glutamine, 50 μM 2-
mercaptoethanol, and 1,000 U/ml LIF (Chemicon). Murine CGR8 ES cells 
were maintained on 0.1% gelatin-coated tissue culture plates in Glasgow 
modified Eagle’s medium supplemented with 10% FBS, 1X nonessential 
amino acids, 2 mM L-glutamine, 50 μM 2-mercaptoethanol, and 100 U/ml 
LIF. All ES cell lines used in present study are of H-2Kb MHC haplotype. 
Induced pluripotent stem cells (iPSCs) AT25 were maintained in murine 
ES cell culture media and originally derived from tail tip fibroblasts of 
mouse (kind gift from Rudolf Jänisch (Whitehead Institute, USA) and 
Alexander Meissner (Harvard Stem cell Institute, USA). C57sv fibroblasts 
were grown in DMEM containing 10% FBS and the YAC-1 lymphoma cells 
were cultured in Iscove’s modified Dulbecco’s medium (IMDM) 
supplemented with 10% FBS. All culture media and reagents were 
supplied by Invitrogen (Karlsruhe, Germany). In all analyses, the cells 
were stimulated with 100 ng/ml interferon gamma (IFNγ) for 2 days prior to 
analysis. 
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V.2.2. RT-PCR and quantative RT-PCR 
 
Total RNA was isolated from human ES cells, murine C57sv fibroblasts, 
murine ES cells, scrambled siRNA treated ES cells and STAT3 siRNA 
treated ES cells using TRIzol Reagent (Invitrogen). DNase I-treated total 
RNA (500 ng or 1 μg) was reverse-transcribed using Superscript II RTase 
(Invitrogen) and random hexamers for priming. cDNA was diluted 1:4 with 
sterile tri-destilled water and 5 μl were amplified using JumpStartTM 
RedTaq ReadyMixTM PCR Reaction Mix (Sigma). Negative controls were 
generated in RT reactions in which all reaction components were included 
except reverse transcriptase. Reactions were terminated at the 
exponential phase of amplification and products were analyzed by 1.5% 
agarose gel electrophoresis. For quantitative RT-PCR the cDNA probes 
were diluted 1:20 and 2 μl was amplified using SYBR Advantage qPCR 
Premix (Clontech Laboratories, Inc. Takara bio Company) in triplicate for 
each sample and each gene. Real-time PCRs were performed in a 7500 
Standard System Real time Cycler (Applied Biosystems) and analyzed 
with SDSShell 1.4 software (Applied Biosystems). GAPDH was used for 
normalization of expression levels of individual genes.  
 
 
V.2.3. STAT3 knock down and its validation in ESCs 
 
STAT3 mRNA in murine ES cells was downregulated by using pre-
designed small interfering RNA (siRNA) specific for STAT3 gene (Oligo ID 
s74452, Ambion). All-star scrambled siRNA conjugated to Alexa Fluor 647 
was used as a negative control. One day before STAT3 knock down, 
100,000 ES cells were plated in each 0.1% gelatine-coated well of a 6-well 
plate. Next day, the cells were transfected with respective siRNA using 
Opti-MEM serum reduced medium and Lipofectamine 2000 (Invitrogen) for 
18 hrs. After 18 hrs, ES cell media was refreshed and all experiments 
were performed after 48 h of lipofection. STAT3 KD in ES cells was 
validated by qRT-PCR and immunoblotting. IFNγ (100 ng/ml) was added to 
ESCs.at the time of lipofection with siRNA  
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V.2.4. Immunoblotting  
 
For immunoblotting, proteins were isolated using protein lysing buffer (10 
mM Tris-HCl, pH 7.5; 150 mM NaCl; 1% Triton X-100; 5 mM EDTA; 1% 
protease inhibitor cocktail (sigma) and 1% phosphatase inhibitor cocktail 
(sigma)). 15 μg of protein was loaded per lane of 10% seperating gel and 
4% stacking gel and run by PolyAcrylamide Gel Electrophoresis (SDS-
PAGE) (Bio-Rad, www.bio-rad.com). Proteins were transferred onto 
methanol-activated PVDF transfer membrane using wet transfer system 
(Schleicher and Schuell, BioScience) in transfer buffer (25mM Tris, 
192mM Glycine and 10% methanol). The membrane was blocked by 5% 
skimmed milk for 1 h at room temperature, incubated with the primary 
antibodies overnight at 4°C and proteins of interest were detect by 
incubation with alkaline phosphatase-conjugated secondary antibodies for 
30 min at room temperature. The signal was detected using 
chemiluminescent substrate by incubating the membrane in CDP-star 
(Applied Biosystems) buffer (2.5 M 2-amino 2-methyl-1-propanol,20mM 
MgCl2) for 1-2 min and subsequent exposure of x-ray film (18x24cm, 
28906836, Amersham Hyperfilm ECL). The list of antibodies used is 
provided in Table in Chapter V1.9. 
 
 
 
V.2.5. Flow cytometric analyses 
 
C57sv fibroblasts and undifferentiated ES cells were dissociated using 
0.05% Trypsin-EDTA (Invitrogen) and 2-5x105 cells were stained for 30 
minutes at 4°C in 100 μl of 0.1% FBS in PBS containing an appropriate 
dilution of a desired antibody for surface markers. For detection of 
pSTAT1, intracellular staining was performed by fixing the cells using 2% 
paraformaldyhyde for 10-15 min at room temperature followed by 
permealization using ice cold methanol for 30 min on ice. Cells were then 
stained with specific pSTAT1 antibody or proper isotype control. Flow 
cytometric analyses were performed on a FACScan (BD Biosciences), and 
data were analyzed using WinMDI2.8 software (BD Pharmingen). Dead 
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cells were excluded by gating on viable cells on the basis of staining with 
propidium iodide or 7-aminoactinomycin D and 10,000 events were 
acquired for each analysis. Primary antibodies used were phycoerythrin 
(PE)-conjugated anti-H2Kb (clone AF6-88.5; BD Pharmingen, cat. no. 
553570, 1:100), biotin conjugated anti-IFNγ-receptor α-chain (clone GR20, 
BD Pharmingen, cat. No. 558771, dilution 1:100), purified anti-IFNγ-
receptor β-chain antibody (BD Pharmingen, cat. no. 559917, dilution 
1:100), Alexa Fluor 488-conjugated anti-pStat1 (pY701) (BD Pharmingen, 
cat. No. 612596, dilution 1:10), Alexa Fluor 488 anti-IgG2a (clone MOPC-
173, cat. No. 558055, BD Pharmingen, dilution 1:10). PE- or straptividin-
conjugated secondary antibodies and all isotype control antibodies were 
purchased from BD Pharmingen or Santa Cruz Biotechnology Inc (Santa 
Cruz).  
 
V.2.6. Luciferase reporter assay 
 
Luciferase reporter assay was performed to determine the promoter 
response to IFNγ in native and STAT3 KD ES cells. For the assay, 10,000 
ESCs were plated in each well of a 96-well flat-bottom white plate (Cat 
no.136101, Nunc) that was pre-coated with 0.1% gelatine and transiently 
transfected with a mixture of vectors (25ng/well). This mixture is composed 
of the STAT1/STAT1-responsive firefly luciferase construct encoding the 
firefly luciferase reporter gene under the control of a minimal (m) CMV 
promoter and tandem repeats of the IFNγ activation sequence (GAS) 
response element and an another vector with constitutively expressing 
Renilla luciferase, which serves as an internal control for normalizing 
transfection efficiencies and monitoring cell viability (Cignal GAS Reporter 
(luc) Kit, cat. no. CCS-009L, SA Biosciences) using Lipofectamine 2000 
(Invitrogen) for 48h. In parallel, ES cells were treated with scrambled or 
STAT3 siRNA for the same period of time. IFNγ was added to the cells 6h 
before the measurement of luciferase activity. Luciferase activity was 
measured by Dual Luciferase Reporter assay system (Promega) as 
specified by the manufacturer. 
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V.2.7. Teratoma formation by ES cells in mice 
 
Control si647 and STAT3 KD murine aPIG ES cells were trypsinized, 
washed twice with PBS, and one million ES cells were injected 
subcutaneously in 200 μl PBS into the interscapular region of Rag2-/-γc-/-. 
Both control and STAT3 KD ES cells were injected into the same mice 
(N=3) but opposite sides to measure the kinetic of teratoma growth. The 
size of teratoma formation was measured every week using digital caliper 
gauge. 
 
V.2.8. Activation and isolation of ovalbumin-specific CTLs  
 
In vivo activation of ova-specific CTLs was performed by i.p. injection of 
ovalbumin (Sigma-Aldrich; 2.5 μg per mouse in 2 mg/ml solution of SDA in 
500μl ml PBS) into OT-1 transgenic mice. Injections were performed twice 
at day 0 and 7. After 14 days, spleenocytes were harvested from these 
mice and cultured for 1 week in RPMI medium supplemented with 10% 
FBS, 100 U/ml IL-2 and 10 μM SIINFEKL,. After three weeks of ova (2 
weeks) and SIINFEKL (1 week) stimulation, CTLs were harvested using a 
positive-selection magnetic cell sorting kit (Miltenyi Biotech) with 
antibodies directed against CD8a molecules (clone Ly-2) specifically 
expressed on T cells.  
 
V.2.9. Activation and isolation of syngenic NK cells  
 
In vivo activation of NK cells was performed by i.p. injection of poly(I:C) 
(Sigma-Aldrich; 200 μg per mouse in 200 μl of PBS buffer) into wild type 
C57BL/6 mice 48h before mice were sacrificed and spleenocytes isolated. 
After lysis of erythrocytes using red blood lytic buffer, NK cells were 
purified using a positive-selection magnetic cell sorting kit (Miltenyi 
Biotech) with antibodies directed against CD49b molecules (clone DX5) 
specifically expressed on NK cells. The purity of 90% was achieved as 
assessed by flow cytometry analysis.  
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V.2.10. 51Cr-release cytotoxicity assay 
To perform NK cell or T cell cytotoxicity assays, target cells (1X 106) were 
labeled with 10 μl (1000 counts per second, cps) of Na2 51CrO4 (Hartmann-
Analytic GmbH) for 1h at 37°C. NK cells or Ova-specific CTLs (effector 
cells) were plated at the appropriate densities to achieve the desired 
effector-to-target (E:T) ratios in the range of 1:12.5 -1:100. First, 100 μl 
culture media without any cells was added into wells for E:T ratio of 1:12.5, 
1:25, 1:50 and spontaneous release wells (in triplicates) of a 96-well plate. 
200 μl containing 6X 105 of effector cells were then added only into the 
wells of 1:100 E:T ratio and 100 μl of effector cells from 1:100 wells were 
transfered into 1:50 well containing already 100 μl of culture media. Now 
after mixing the cell suspension in 1:50 ratio wells, 100 μl media was 
transferred into 1:25 ratio wells and then into 1:12.5 ratio wells following 
the serial dilution principle. After pipetting the effector cells into the wells, 
3X 103 target cells in 100 μl media were transferred into the each well. For 
maximum release, 100 μl of 10% Triton-X100 was transferred into the well 
containing only 100μl of target cells. After 4 hours of incubation, plates 
were centrifuged to take cell culture supernatants (100 μl per well) and the 
radioactivity in the supernatant was determined in a gamma counter 
(PerkinElmer Life and Analytical Sciences, Gamma counter). The 
percentage of specific 51Cr-release was determined by the following 
equation: specic lysis (%) = [(experimental release-spontaneous 
release)/(maximum release-spontaneous release)] X 100. All groups were 
run in triplicate and all experiments were performed at least three times. 
 
V.2.11. Interferon-γ enzyme-linked immunosorbent assay 
 
The concentration of IFNγ released by activated CTLs into medium with 
various target cells at an E:T ratio of 50:1 was determined in the cell 
culture supernatant using DuoFlow IFNγ ELISA kit (R&D systems, Cat No. 
MFI00) according to the manufacturer’s instructions using the 96-well flat 
bottom transparent plates (cat no.456537, MaxiSorp96-well, Nunc). Murine 
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recombinant IFNγ provided in the kit was used to generate the standard 
curve. According to the kit, the optical density of each well was determined 
using a microplate reader (GenyosPro, Tecan) and the 450 nm 
absorbance filter. 
 
V.2.12. Generation of ES cell-derived cardiomyocytes 
 
ES-CMs were generated from a transgenic clones of D3 ES cells (αPIG44) 
and ova-expressing αPIG44 ES cell subclone A4 by modification of a 
previously used mass culture protocol (Kolossov et al. 2006). 
Cardiomyocytes that can be obtained from these transgenic ES cell lines 
after puromycin selection are predominantly of atrial-like and pacemaker-
like type. To initiate the ES cell differentiation, 1x 106 ES cells were 
suspended in 14 ml of differentiation medium (IMDM supplemented with 
20% FBS, 10 μM 2-mercaptoethanol, and 1X nonessential amino acids) 
and incubated in non-adherent plates under continuous horizontal 
agitation to allow formation of EBs. After 2 days the EBs were diluted into 
fresh nonadherent plates to a density of 1,000 EBs per 14 ml of 
differentiation medium per plate. The differentiation of EBs continued on a 
horizontal shaker without medium change until EGFP-positive EBs 
occurred on days 8-9 of differentiation. At this time, fresh medium 
supplemented with puromycin (8 μg/ml) was added to select for ES-CMs. 
Medium containing puromycin was changed every 2-3 days until pure 
beating cardiac clusters were collected at day 16 of differentiation. For 
analyses, cardiac clusters were enzymatically dissociated into single ES-
CM after 7 days of puromycin treatment. 
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